Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Hematology & Oncology
Published in: Journal of Hematology & Oncology 1/2021

Open Access 01-12-2021 | Review

MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies

Authors: Seyed Esmaeil Ahmadi, Samira Rahimi, Bahman Zarandi, Rouzbeh Chegeni, Majid Safa

Published in: Journal of Hematology & Oncology | Issue 1/2021

Login to get access

Abstract

MYC oncogene is a transcription factor with a wide array of functions affecting cellular activities such as cell cycle, apoptosis, DNA damage response, and hematopoiesis. Due to the multi-functionality of MYC, its expression is regulated at multiple levels. Deregulation of this oncogene can give rise to a variety of cancers. In this review, MYC regulation and the mechanisms by which MYC adjusts cellular functions and its implication in hematologic malignancies are summarized. Further, we also discuss potential inhibitors of MYC that could be beneficial for treating hematologic malignancies.
Literature
1.
Chen H, Liu H, Qing G. Targeting oncogenic Myc as a strategy for cancer treatment. Signal Transduct Target Ther. 2018;3:1–7.PubMedPubMedCentral
2.
Dang CV, O’Donnell KA, Zeller KI, Nguyen T, Osthus RC, Li F. The c-Myc target gene network. In: Seminars in cancer biology. 2006.
3.
4.
Adhikary S, Eilers M. Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol. 2005;6:635–45.PubMedCrossRef
5.
Pelengaris S, Khan M, Evan G. c-MYC: more than just a matter of life and death. Nat Rev Cancer. 2002;2:764–76.PubMedCrossRef
6.
Nie Z, Gangqing H, Wei G, Cui K, Yamane A, Resch W, et al. c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells. Cell. 2012;151:68–79.PubMedPubMedCentralCrossRef
7.
Thomas LR, Tansey WP. Proteolytic control of the oncoprotein transcription factor Myc. Adv Cancer Res. 2011;110:77–106.PubMedCrossRef
8.
Sorrentino V, Drozdoff V, McKinney MD, Zeitz L, Fleissner E. Potentiation of growth factor activity by exogenous c-myc expression. Proc Natl Acad Sci U S A. 1986;83:8167–71.PubMedPubMedCentralCrossRef
9.
Karn J, Watson JV, Lowe AD, Green SM, Vedeckis W. Regulation of cell cycle duration by c-myc levels. Oncogene. 1989;4(6):773–87.
10.
11.
Armelin HA, Armelin MCS, Kelly K, Stewart T, Leder P, Cochran BH, et al. Functional role for c-myc in mitogenic response to platelet-derived growth factor. Nature. 1984;310:655–60.PubMedCrossRef
12.
Kaczmarek L, Hyland JK, Watt R, Rosenberg M, Baserga R. Microinjected c-myc as a competence factor. Science (80- ). 1985;228:1313–5.CrossRef
13.
Amati B, Alevizopoulos K, Vlach J. Myc and the cell cycle. Front Biosci. 1998;22:d250–68.CrossRef
14.
Britton S, Salles B, Calsou P. c-Myc protein is degraded in response to UV irradiation. Cell Cycle. 2008;7:63–70.PubMedCrossRef
15.
Jiang M, Li Y, Yang Y, Oncogene JW. c-Myc degradation induced by DNA damage results in apoptosis of CHO cells. Oncogene. 2003;22:3252–9.PubMedCrossRef
16.
Lu H, Meng L, Huang M, Zhu H, et al. DNA damage, c-myc suppression and apoptosis induced by the novel topoisomerase II inhibitor, salvicine, in human breast cancer MCF-7 cells. Cancer Chemother Pharmacol. 2005;55:286–94.PubMedCrossRef
17.
Herbst A, Hemann MT, Tworkowski KA, Salghetti SE, Lowe SW, Tansey WP. A conserved element in Myc that negatively regulates its proapoptotic activity. EMBO Rep. 2005;6:177–83.PubMedPubMedCentralCrossRef
18.
Popov N, Herold S, Llamazares M, Schülein C, Eilers M. Fbw7 and Usp28 regulate myc protein stability in response to DNA damage. Cell Cycle. 2007;6:2327–31.PubMedCrossRef
19.
Herold S, Wanzel M, Beuger V, Frohme C. Negative regulation of the mammalian UV response by Myc through association with Miz-1. Mol Cell. 2002;10:509–21.PubMedCrossRef
20.
Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, et al. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992;69:119–28.PubMedCrossRef
21.
Inoue K, Zindy F, Randle DH, Rehg JE, Sherr CJ. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 2001;15:2934–9.PubMedPubMedCentralCrossRef
22.
Muthalagu N, Junttila MR, Wiese KE, Wolf E, Morton J, Bauer B, et al. BIM is the primary mediator of MYC-induced apoptosis in multiple solid tissues. Cell Rep. 2014;8:1347–53.PubMedPubMedCentralCrossRef
23.
24.
25.
Bahram F, Von Der Lehr N, Cetinkaya C, Larsson LG. c-Myc hot spot mutations in lymphomas result in inefficient ubiquitination and decreased proteasome-mediated turnover. Blood. 2000;95:2104–10.PubMedCrossRef
26.
Malempati S, Tibbitts D, Cunningham M, Akkari Y, Olson S, Fan G, et al. Aberrant stabilization of c-Myc protein in some lymphoblastic leukemias. Leukemia. 2006;20:1572–81.PubMedPubMedCentralCrossRef
27.
Salghetti SE, Kim SY, Tansey WP. Destruction of Myc by ubiquitin-mediated proteolysis: Cancer-associated and transforming mutations stabilize Myc. EMBO J. 1999;18:717–26.PubMedPubMedCentralCrossRef
28.
29.
Schick M, Habringer S, Nilsson JA, Keller U. Pathogenesis and therapeutic targeting of aberrant MYC expression in haematological cancers. Br J Haematol. 2017;179:727–38.CrossRef
30.
31.
Chung HJ, Levens D. c-Myc expression: keep the noise down! Mol Cells. 2005;20:157–66.PubMed
32.
Levens D. How the c-myc promoter works and why it sometimes does not. J Natl Cancer Inst Monogr. 2008;2008:41–3.CrossRef
33.
34.
Buchholz M, Schatz A, Wagner M, Michl P, Linhart T, Adler G, et al. Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+/calcineurin signaling pathway. EMBO J. 2006;25:3714–24.PubMedPubMedCentralCrossRef
35.
Mognol GP, de Araujo-Souza PS, Robbs BK, Teixeira LK, Viola JP. Transcriptional regulation of the c-Myc promoter by NFAT1 involves negative and positive NFAT-responsive elements. Cell Cycle. 2012;11:1014–28.PubMedCrossRef
36.
Carabet LA, Rennie PS, Cherkasov A. Therapeutic inhibition of myc in cancer. Structural bases and computer-aided drug discovery approaches. Int J Mol Sci. 2019;20:120.CrossRef
37.
Rottmann S, Lüscher B. The Mad side of the Max network: antagonizing the function of Myc and more. Curr Top Microbiol Immunol. 2006;302:63–122.PubMed
38.
Henriksson M, Bakardjiev A, Klein G, Lüscher B. Phosphorylation sites mapping in the N-terminal domain of c-myc modulate its transforming potential. Oncogene. 1993;8:3199–209.PubMed
39.
Lutterbach B, Hann SR. Hierarchical phosphorylation at N-terminal transformation-sensitive sites in c-Myc protein is regulated by mitogens and in mitosis. Mol Cell Biol. 1994;14:5510–22.PubMedPubMedCentral
40.
Sears R, Nuckolls F, Haura E, Taya Y, Tamai K, Nevins JR. Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability. Genes Dev. 2000;14:2501–14.PubMedPubMedCentralCrossRef
41.
Tsai WB, Aiba I, Long Y, Lin HK, Feun L, Savaraj N, et al. Activation of Ras/PI3K/ERK pathway induces c-Myc stabilization to upregulate argininosuccinate synthetase, leading to arginine deiminase resistance in melanoma cells. Cancer Res. 2012;72:2622–33.PubMedPubMedCentralCrossRef
42.
Sears R, Leone G, DeGregori J, Nevins JR. Ras enhances Myc protein stability. Mol Cell. 1999;3:169–79.PubMedCrossRef
43.
Devaiah BN, Case-Borden C, Gegonne A, Hsu CH, Chen Q, Meerzaman D, et al. BRD4 is a histone acetyltransferase that evicts nucleosomes from chromatin. Nat Struct Mol Biol. 2016;23:540–8.PubMedPubMedCentralCrossRef
44.
Devaiah BN, Mu J, Akman B, Uppal S, Weissman JD, Cheng D, et al. MYC protein stability is negatively regulated by BRD4. Proc Natl Acad Sci U S A. 2020;117:13457–67.PubMedPubMedCentralCrossRef
45.
Barone MV, Courtneidge SA. Myc but not Fos rescue of PDGF signalling block caused by kinase-inactive Src. Nature. 1995;378:509–12.PubMedCrossRef
46.
Chiariello M, Marinissen MJ, Gutkind JS. Regulation of c-myc expression by PDGF through Rho GTPases. Nat Cell Biol. 2001;3:580–6.PubMedCrossRef
47.
Eichhorn PJ, Creyghton MP, Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim Biophys Acta. 2009;1795:1–15.PubMed
48.
Sablina AA, Hector M, Colpaert N, Hahn WC. Identification of PP2A complexes and pathways involved in cell transformation. Cancer Res. 2010;70:10474–84.PubMedPubMedCentralCrossRef
49.
Ruvolo PP. The broken “Off” switch in cancer signaling: PP2A as a regulator of tumorigenesis, drug resistance, and immune surveillance. BBA Clin. 2016;6:87–99.PubMedPubMedCentralCrossRef
50.
Arnold HK, Sears RC. Protein phosphatase 2A regulatory subunit B56alpha associates with c-myc and negatively regulates c-myc accumulation. Mol Cell Biol. 2006;26:2832–44.PubMedPubMedCentralCrossRef
51.
Lin CF, Chen CL, Chiang CW, Jan MS, Huang WC, Lin YS. GSK-3beta acts downstream of PP2A and the PI 3-kinase-Akt pathway, and upstream of caspase-2 in ceramide-induced mitochondrial apoptosis. J Cell Sci. 2007;120:2935–43.PubMedCrossRef
52.
53.
Yeh E, Cunningham M, Arnold H, Chasse D, Monteith T, Ivaldi G, et al. A signalling pathway controlling c-Myc degradation that impacts oncogenic transformation of human cells. Nat Cell Biol. 2004;6:308–18.PubMedCrossRef
54.
Welcker M, Orian A, Jin J, Grim JE, Harper JW, Eisenman RN, et al. The Fbw7 tumor suppressor regulates glycogen synthase kinase 3 phosphorylation-dependent c-Myc protein degradation. Proc Natl Acad Sci U S A. 2004;101:9085–90.PubMedPubMedCentralCrossRef
55.
Arnold HK, Zhang X, Daniel CJ, Tibbitts D, Escamilla-Powers J, Farrell A, et al. The Axin1 scaffold protein promotes formation of a degradation complex for c-Myc. EMBO J. 2009;28:500–12.PubMedPubMedCentralCrossRef
56.
Zhou XZ, Kops O, Werner A, Lu PJ, Shen M, Stoller G, et al. Pin1-dependent prolyl isomerization regulates dephosphorylation of Cdc25C and tau proteins. Mol Cell. 2000;6:873–83.PubMedCrossRef
57.
Farrell AS, Pelz C, Wang X, Daniel CJ, Wang Z, Su Y, et al. Pin1 regulates the dynamics of c-Myc DNA binding to facilitate target gene regulation and oncogenesis. Mol Cell Biol. 2013;33:2930–49.PubMedPubMedCentralCrossRef
58.
Adhikary S, Marinoni F, Hock A, Hulleman E, Popov N, Beier R, et al. The ubiquitin ligase HectH9 regulates transcriptional activation by Myc and is essential for tumor cell proliferation. Cell. 2005;123:409–21.PubMedCrossRef
59.
Yada M, Hatakeyama S, Kamura T, Nishiyama M, Tsunematsu R, Imaki H, et al. Phosphorylation-dependent degradation of c-Myc is mediated by the F-box protein Fbw7. EMBO J. 2004;23:2116–25.PubMedPubMedCentralCrossRef
60.
von der Lehr N, Johansson S, Wu S, Bahram F, Castell A, Cetinkaya C, et al. The F-box protein Skp2 participates in c-Myc proteosomal degradation and acts as a cofactor for c-Myc-regulated transcription. Mol Cell. 2003;11:1189–200.PubMedCrossRef
61.
Choi SH, Wright JB, Gerber SA, Cole MD. Myc protein is stabilized by suppression of a novel E3 ligase complex in cancer cells. Genes Dev. 2010;24:1236–41.PubMedPubMedCentralCrossRef
62.
Paul I, Ahmed SF, Bhowmik A, Deb S, Ghosh MK. The ubiquitin ligase CHIP regulates c-Myc stability and transcriptional activity. Oncogene. 2013;32:1284–95.PubMedCrossRef
63.
64.
Welcker M, Clurman BE. FBW7 ubiquitin ligase: a tumour suppressor at the crossroads of cell division, growth and differentiation. Nat Rev Cancer. 2008;8:83–93.PubMedCrossRef
65.
van Drogen F, Sangfelt O, Malyukova A, Matskova L, Yeh E, Means AR, et al. Ubiquitylation of cyclin E requires the sequential function of SCF complexes containing distinct hCdc4 isoforms. Mol Cell. 2006;23:37–48.PubMedCrossRef
66.
Grim JE, Gustafson MP, Hirata RK, Hagar AC, Swanger J, Welcker M, et al. Isoform- and cell cycle-dependent substrate degradation by the Fbw7 ubiquitin ligase. J Cell Biol. 2008;181:913–20.PubMedPubMedCentralCrossRef
67.
Kim SY, Herbst A, Tworkowski KA, Salghetti SE, Tansey WP. Skp2 regulates Myc protein stability and activity. Mol Cell. 2003;11:1177–88.PubMedCrossRef
68.
Chung YM, Kim JS, Yoo YD. A novel protein, Romo1, induces ROS production in the mitochondria. Biochem Biophys Res Commun. 2006;347:649–55.PubMedCrossRef
69.
Chung JS, Lee SB, Park SH, Kang ST, Na AR, Chang TS, et al. Mitochondrial reactive oxygen species originating from Romo1 exert an important role in normal cell cycle progression by regulating p27(Kip1) expression. Free Radic Res. 2009;43:729–37.PubMedCrossRef
70.
Lee SB, Kim JJ, Chung JS, Lee MS, Lee KH, Kim BS, et al. Romo1 is a negative-feedback regulator of Myc. J Cell Sci. 2011;124:1911–24.PubMedCrossRef
71.
Li S, Jiang C, Pan J, Wang X, Jin J, Zhao L, et al. Regulation of c-Myc protein stability by proteasome activator REGγ. Cell Death Differ. 2015;22:1000–11.PubMedCrossRef
72.
Mao I, Liu J, Li X, Luo H. REGgamma, a proteasome activator and beyond? Cell Mol Life Sci. 2008;65:3971–80.PubMedCrossRef
73.
74.
Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, et al. Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet. 2011;7:e1002360.PubMedPubMedCentralCrossRef
75.
76.
McConnell MJ, Chevallier N, Berkofsky-Fessler W, Giltnane JM, Malani RB, Staudt LM, et al. Growth suppression by acute promyelocytic leukemia-associated protein PLZF is mediated by repression of c-myc expression. Mol Cell Biol. 2003;23:9375–88.PubMedPubMedCentralCrossRef
77.
78.
Cannell IG, Kong YW, Bushell M. How do microRNAs regulate gene expression? Biochem Soc Trans. 2008;36:1224–31.PubMedCrossRef
79.
Valencia-Sanchez MA, Liu J, Hannon GJ, Parker R. Control of translation and mRNA degradation by miRNAs and siRNAs. Genes Dev. 2006;20:515–24.PubMedCrossRef
80.
Cannell IG, Kong YW, Johnston SJ, Chen ML, Collins HM, Dobbyn HC, et al. p38 MAPK/MK2-mediated induction of miR-34c following DNA damage prevents Myc-dependent DNA replication. Proc Natl Acad Sci U S A. 2010;107:5375–80.PubMedPubMedCentralCrossRef
81.
82.
Mateyak MK, Obaya AJ, Adachi S, Sedivy JM. Phenotypes of c-Myc-deficient rat fibroblasts isolated by targeted homologous recombination. Cell Growth Differ. 1997;8(10):1039–48.
83.
Sears RC. The life cycle of C-myc: from synthesis to degradation. Cell Cycle. 2004;3(9):1133-37.
84.
Chanu SI, Sarkar S. The paradox of c-Myc proto-oncogene and its diverse functions. Cell Dev Biol. 2014;3:3.
85.
Eilers M, Schirm S, Bishop JM. The MYC protein activates transcription of the α-prothymosin gene. EMBO J Eur Mol Biol Org. 1991;10:133–41.CrossRef
86.
Schuhmacher M, Staege MS, Pajic A, Polack A, Weidle UH, Bornkamm GW, et al. Control of cell growth by c-Myc in the absence of cell division. Curr Biol. 1999;9:1255–8.PubMedCrossRef
87.
88.
Heikkila R, Schwab G, Wickstrom E, Loke SL, Pluznik DH, Watt R, et al. A c-myc antisense oligodeoxynucleotide inhibits entry into S phase but not progress from G0 to G1. Nature. 1987;328:445–9.PubMedCrossRef
89.
Wickstrom EL, Bacon TA, Gonzalez A, Freeman DL, Lyman GH, Wickstrom E. Human promyelocytic leukemia HL-60 cell proliferation and c-myc protein expression are inhibited by anantisense pentadecadeoxynucleotide targeted against c-myc mRNA. Proc Natl Acad Sci U S A. 1988;85:1028–32.PubMedPubMedCentralCrossRef
90.
Wang H, Mannava S, Grachtchouk V, Zhuang D, Soengas MS, Gudkov AV, et al. c-Myc depletion inhibits proliferation of human tumor cells at various stages of the cell cycle. Oncogene. 2008;27:1905–15.PubMedCrossRef
91.
92.
Hurlin PJ, Huang J. The MAX-interacting transcription factor network. Semin Cancer Biol. 2006;16:265–74.PubMedCrossRef
93.
Berns K, Hijmans EM, Bernards R. Repression of c-Myc responsive genes in cycling cells causes G1 arrest through reduction of cyclin E/CDK2 kinase activity. Oncogene. 1997;15:1347–56.PubMedCrossRef
94.
Cerni C, Skrzypek B, Popov N, Sasgary S, Schmidt G, Larsson LG, et al. Repression of in vivo growth of Myc/Ras transformed tumor cells by Mad1. Oncogene. 2002;21:447–59.PubMedCrossRef
95.
Menssen A, Hermeking H. Characterization of the c-MYC-regulated transcriptome by SAGE: identification and analysis of c-MYC target genes. Proc Natl Acad Sci U S A. 2002;99:6274–9.PubMedPubMedCentralCrossRef
96.
Gordan JD, Bertout JA, Hu CJ, Diehl JA, Simon MC. HIF-2α promotes hypoxic cell proliferation by enhancing c-Myc transcriptional activity. Cancer Cell Cancer Cell. 2007;11:335–47.PubMedCrossRef
97.
98.
99.
100.
Xu H, Wang Z, Jin S, Hao H, Zheng L, Zhou B, et al. Dux4 induces cell cycle arrest at G1 phase through upregulation of p21 expression. Biochem Biophys Res Commun. 2014;446:235–40.PubMedCrossRef
101.
Schorl C, Sedivy JM. Loss of protooncogene c-Myc function impedes G1 phase progression both before and after the restriction point. Mol Biol Cell. 2003;14:823–35.PubMedPubMedCentralCrossRef
102.
Chellappan SP, Hiebert S, Mudryj M, Horowitz JM, Nevins JR. The E2F transcription factor is a cellular target for the RB protein. Cell. 1991;65:1053–61.PubMedCrossRef
103.
Weintraub SJ, Chow KNB, Luo RX, Zhang SH, He S, Dean DC. Mechanism of active transcriptional repression by the retinoblastoma protein. Nature. 1995;375:812–6.PubMedCrossRef
104.
105.
106.
107.
Pavlides SC, Lecanda J, Daubriac J, Pandya UM, Gama P, Blank S, et al. TGF-β activates APC through Cdh1 binding for Cks1 and Skp2 proteasomal destruction stabilizing p27kip1 for normal endometrial growth. Cell Cycle. 2016;15:931–47.PubMedPubMedCentralCrossRef
108.
Hydbring P, Malumbres M, Sicinski P. Non-canonical functions of cell cycle cyclins and cyclin-dependent kinases. Nat Rev Mol Cell Biol. 2016;17:280–92.PubMedPubMedCentralCrossRef
109.
Sherr CJ, Roberts JM. Living with or without cyclins and cyclin-dependent kinases. Genes Dev. 2004;18:2699–711.PubMedCrossRef
110.
Sherr CJ, Roberts JM. CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev. 1999;13:1501–12.PubMedCrossRef
111.
Pavletich NP. Mechanisms of cyclin-dependent kinase regulation: structures of Cdks, their cyclin activators, and Cip and INK4 inhibitors. J Mol Biol. 1999;287:821–8.PubMedCrossRef
112.
Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature. 1993;366:704–7.PubMedCrossRef
113.
Reynisdóttir I, Massagué J. The subcellular locations of pl5(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. Genes Dev. 1997;11:492–503.PubMedCrossRef
114.
Ouelle DE, Zindy F, Ashmun RA, Sherr CJ. Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell. 1995;83:993–1000.CrossRef
115.
Weber JD, Jeffers JR, Rehg JE, Randle DH, Lozano G, Roussel MF, et al. p53-independent functions of the p19(ARF) tumor suppressor. Genes Dev. 2000;14:2358–65.PubMedPubMedCentralCrossRef
116.
McKeller RN, Fowler JL, Cunningham JJ, Warner N, Smeyne RJ, Zindy F, et al. The Arf tumor suppressor gene promotes hyaloid vascular regression during mouse eye development. Proc Natl Acad Sci U S A. 2002;99:3848–53.PubMedPubMedCentralCrossRef
117.
Weber JD, Taylor LJ, Roussel MF, Sherr CJ, Bar-Sagi D. Nucleolar Arf sequesters Mdm2 and activates p53. Nat Cell Biol. 1999;1:20–6.PubMedCrossRef
118.
Datta A, Nag A, Pan W, Hay N, Gartel AL, Colamonici O, et al. Myc-ARF (alternate reading frame) interaction inhibits the functions of Myc. J Biol Chem. 2004;279:36698–707.PubMedCrossRef
119.
Tu WB, Helander S, Pilstål R, Hickman KA, Lourenco C, Jurisica I, et al. Myc and its interactors take shape. Biochim Biophys Acta Gene Regul Mech. 2015;1849:469–83.CrossRef
120.
Gregory MA, Qi Y, Hann SR. The ARF tumor suppressor: keeping Myc on a leash. Cell Cycle. 2005;4(2):249–52.
121.
Conzen SD, Gottlob K, Kandel ES, Khanduri P, Wagner AJ, O’Leary M, et al. Induction of cell cycle progression and acceleration of apoptosis are two separable functions of c-Myc: transrepression correlates with acceleration of apoptosis. Mol Cell Biol. 2000;20:6008–18.PubMedPubMedCentralCrossRef
122.
Oster SK, Mao DYL, Kennedy J, Penn LZ. Functional analysis of the n-terminal domain of the myc oncoprotein. Oncogene. 2003;22:1998–2010.PubMedCrossRef
123.
Soucek L, Jucker R, Panacchia L, Ricordy R, Tatò F, Nasi S. Omomyc, a potential Myc dominant negative, enhances Myc-induced apoptosis. Cancer Res. 2002;62(12):3507–10.
124.
Lee EW, Lee MS, Camus S, Ghim J, Yang MR, Oh W, et al. Differential regulation of p53 and p21 by MKRN1 E3 ligase controls cell cycle arrest and apoptosis. EMBO J. 2009;28:2100–13.PubMedPubMedCentralCrossRef
125.
Yagi A, Hasegawa Y, Xiao H, Haneda M, Kojima E, Nishikimi A, et al. GADD34 Induces p53 Phosphorylation and p21/WAF1 Transcription. J Cell Biochem. 2003;90:1242–9.PubMedCrossRef
126.
Wu S, Cetinkaya C, Munoz-Alonso MJ, Von Der Lehr N, Bahram F, Beuger V, et al. Myc represses differentiation-induced p21CIP1 expression via Miz-1-dependent interaction with the p21 core promoter. Oncogene. 2003;22:351–60.PubMedCrossRef
127.
García-Gutiérrez L, Delgado MD, León J. Myc oncogene contributions to release of cell cycle brakes. Genes (Basel). 2019;10:244.CrossRef
128.
129.
Leone G, Sears R, Huang E, Rempel R, Nuckolls F, Park CH, et al. Myc requires distinct E2F activities to induce S phase and apoptosis. Mol Cell. 2001;8:105–13.PubMedCrossRef
130.
Adams MR, Sears R, Nuckolls F, Leone G, Nevins JR. Complex transcriptional regulatory mechanisms control expression of the E2F3 locus. Mol Cell Biol. 2000;20:3633–9.PubMedPubMedCentralCrossRef
131.
Sears R, Ohtani K, Nevins JR. Identification of positively and negatively acting elements regulating expression of the E2F2 gene in response to cell growth signals. Mol Cell Biol. 1997;17:5227–35.PubMedPubMedCentralCrossRef
132.
Rounbehler RJ, Rogers PM, Conti CJ, Johnson DG. Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model. Cancer Res. 2002;62(11):3276–81.
133.
Lupini L, Bassi C, Ferracin M, Bartonicek N, D’Abundo L, Zagatti B, et al. miR-221 affects multiple cancer pathways by modulating the level of hundreds messenger RNAs. Front Genet. 2013;4:64.PubMedPubMedCentralCrossRef
134.
135.
Hermeking H, Rago C, Schuhmacher M, Li Q, Barrett JF, Obaya AJ, et al. Identification of CDK4 as a target of c-MYC. Proc Natl Acad Sci U S A. 2000;97:2229–34.PubMedPubMedCentralCrossRef
136.
Li Z, Van Calcar S, Qu C, Cavenee WK, Zhang MQ, Ren B. A global transcriptional regulatory role for c-Myc in Burkitt’s lymphoma cells. Proc Natl Acad Sci U S A. 2003;100:8164–9.PubMedPubMedCentralCrossRef
137.
Yap CS, Peterson AL, Castellani G, Sedivy JM, Neretti N. Kinetic profiling of the c-Myc transcriptome and bioinformatic analysis of repressed gene promoters. Cell Cycle. 2011;10:2184–96.PubMedPubMedCentralCrossRef
138.
Hanson KD, Shichiri M, Follansbee MR, Sedivy JM. Effects of c-myc expression on cell cycle progression. Mol Cell Biol. 1994;14:5748–55.PubMedPubMedCentral
139.
Kim J, Woo AJ, Chu J, Snow JW, Fujiwara Y, Kim CG, et al. A myc network accounts for similarities between embryonic stem and cancer cell transcription programs. Cell. 2010;143:313–24.PubMedPubMedCentralCrossRef
140.
Born TL, Frost JA, Schönthal A, Prendergast GC, Feramisco JR. c-Myc cooperates with activated Ras to induce the cdc2 promoter. Mol Cell Biol. 1994;14:5710–8.PubMedPubMedCentral
141.
Liu Z-J, Ueda T, Miyazaki T, Tanaka N, Mine S, Tanaka Y, et al. A critical role for cyclin c in promotion of the hematopoietic cell cycle by cooperation with c-Myc. Mol Cell Biol. 1998;18:3445–54.PubMedPubMedCentralCrossRef
142.
143.
Morgan DO. Cyclin-dependent kinases: engines, clocks, and microprocessors. Annu Rev Cell Dev Biol. 1997;13:261–91.PubMedCrossRef
144.
Lolli G, Johnson LN. CAK-Cyclin-dependent activating kinase: a key kinase in cell cycle control and a target for drugs? Cell Cycle. 2005;4(4):572–77.
145.
Cowling VH, Cole MD. The myc transactivation domain promotes global phosphorylation of the RNA polymerase II carboxy-terminal domain independently of direct DNA binding. Mol Cell Biol. 2007;27:2059–73.PubMedPubMedCentralCrossRef
146.
Parker LL, Piwnica-Worms H. Inactivation of the p34cdc2-cyclin B complex by the human WEE1 tyrosine kinase. Science (80- ). 1992;257:1955–7.CrossRef
147.
Galaktionov K, Chen X, Beach D. Cdc25 cell-cycle phosphatase as a target of c-myc. Nature. 1996;382:511–7.PubMedCrossRef
148.
Le Sage C, Nagel R, Egan DA, Schrier M, Mesman E, Mangiola A, et al. Regulation of the p27Kip1 tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J. 2007;26:3699–708.PubMedPubMedCentralCrossRef
149.
Daksis JI, Lu RY, Facchini LM, Marhin WW, Penn LJ. Myc induces cyclin D1 expression in the absence of de novo protein synthesis and links mitogen-stimulated signal transduction to the cell cycle. Oncogene. 1994;9(12):3635–45.
150.
Jansen-Durr P, Meichle A, Steiner P, Pagano M, Finke K, Botz J, et al. Differential modulation of cyclin gene expression by MYC. Proc Natl Acad Sci U S A. 1993;90:3685–9.PubMedPubMedCentralCrossRef
151.
Philipp A, Schneider A, Väsrik I, Finke K, Xiong Y, Beach D, et al. Repression of cyclin D1: a novel function of MYC. Mol Cell Biol. 1994;14:4032–43.PubMedPubMedCentral
152.
Solomon DL, Philipp A, Land H, Eilers M. Expression of cyclin D1 mRNA is not upregulated by Myc in rat fibroblasts. Oncogene. 1995;11(9):1893–97.
153.
Bouchard C, Thieke K, Maier A, Saffrich R, Hanley-Hyde J, Ansorge W, et al. Direct induction of cyclin D2 by Myc contributes to cell cycle progression and sequestration of p27. EMBO J. 1999;18:5321–33.PubMedPubMedCentralCrossRef
154.
Bouchard C, Dittrich O, Kiermaier A, Dohmann K, Menkel A, Eilers M, et al. Regulation of cyclin D2 gene expression by the Myc/Max/Mad network: Myc-dependent TRRAP recruitment and histone acetylation at the cyclin D2 promoter. Genes Dev. 2001;15:2042–7.PubMedPubMedCentralCrossRef
155.
Yu Q, Ciemerych MA, Sicinski P. Ras and Myc can drive oncogenic cell proliferation through individual D-cyclins. Oncogene. 2005;24:7114–9.PubMedCrossRef
156.
Pérez-Roger I, Solomon DLC, Sewing A, Land H. Myc activation of cyclin E/Cdk2 kinase involves induction of cyclin E gene transcription and inhibition of p27(Kip1) binding to newly formed complexes. Oncogene. 1997;14:2373–81.PubMedCrossRef
157.
Zeller KI, Zhao XD, Lee CWH, Kuo PC, Yao F, Yustein JT, et al. Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci U S A. 2006;103:17834–9.PubMedPubMedCentralCrossRef
158.
Qi Y, Tu Y, Yang D, Chen Q, Xiao J, Chen Y, et al. Cyclin A but not cyclin D1 is essential for c-myc-modulated cell-cycle progression. J Cell Physiol. 2007;210:63–71.PubMedCrossRef
159.
Pusch O, Bernaschek G, Eilers M, Hengstschläger M. Activation of c-Myc uncouples DNA replication from activation of G1-cyclin-dependent kinases. Oncogene. 1997;15:649–56.PubMedCrossRef
160.
Barrett JF, Lewis BC, Hoang AT, Alvarez RJ, Dang CV. Cyclin A links c-Myc to adhesion-independent cell proliferation. J Biol Chem. 1995;270:15923–5.PubMedCrossRef
161.
162.
Haeng RS, Kim J, Bae S, Soh JW, Lee YS. Cdk5-mediated phosphorylation of c-Myc on Ser-62 is essential in transcriptional activation of cyclin B1 by cyclin G1. J Biol Chem. 2008;283:15601–10.CrossRef
163.
Yin XY, Grove L, Datta NS, Katula K, Long MW, Prochownik EV. Inverse regulation of cyclin B1 by c-Myc and p53 and induction of tetraploidy by cyclin B1 overexpression. Cancer Res. 2001;61(17):6487–93.
164.
165.
166.
Warner BJ, Blain SW, Seoane J, Massagué J. Myc downregulation by transforming growth factor β required for activation of the p15Ink4b G1 arrest pathway. Mol Cell Biol. 1999;19:5913–22.PubMedPubMedCentralCrossRef
167.
Staller P, Peukert K, Kiermaier A, Seoane J, Lukas J, Karsunky H, et al. Repression of p15INK4b expression by Myc through association with Miz-1. Nat Cell Biol. 2001;3:392–9.PubMedCrossRef
168.
Wiese KE, Walz S, Von Eyss B, Wolf E, Athineos D, Sansom O, et al. The role of MIZ-1 in MYC-dependent tumorigenesis. Cold Spring Harb Perspect Med. 2013;3:a014290.PubMedPubMedCentralCrossRef
169.
Jiang G, Espeseth A, Hazuda DJ, Margolis DM. c-Myc and Sp1 contribute to proviral latency by recruiting histone deacetylase 1 to the human immunodeficiency virus type 1 promoter. J Virol. 2007;81:10914–23.PubMedPubMedCentralCrossRef
170.
Feng XH, Liang YY, Liang M, Zhai W, Lin X. Direct interaction of c-Myc with Smad2 and Smad3 to inhibit TGF-β-mediated induction of the CDK inhibitor p15(Ink4B). Mol Cell. 2016;62:152.PubMedCrossRef
171.
Bouchard C, Lee S, Paulus-Hock V, Loddenkemper C, Eilers M, Schmitt CA. FoxO transcription factors suppress Myc-driven lymphomagenesis via direct activation of Arf. Genes Dev. 2007;21:2775–87.PubMedPubMedCentralCrossRef
172.
Bates S, Phillips AC, Clark PA, Stott F, Peters G, Ludwig RL, et al. p14(ARF) links the tumour suppressors RB and p53. Nature. 1998;395:124–5.PubMedCrossRef
173.
Meyer N, Kim SS, Penn LZ. The Oscar-worthy role of Myc in apoptosis. In: Seminars in cancer biology; 2006. p. 275–87.
174.
175.
Seoane J, Van LH, Massagué J. Myc suppression of the p21Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002;419:729–34.PubMedCrossRef
176.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, Trent JM, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993;75:817–25.PubMedCrossRef
177.
Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell. 1992;71:587–97.PubMedCrossRef
178.
Marhin WW, Chen S, Facchini LM, Fornace AJ, Penn LZ. Myc represses the growth arrest gene gadd45. Oncogene. 1997;14:2825–34.PubMedCrossRef
179.
Mitchell KO, El-Deiry WS. Overexpression of c-Myc inhibits p21(WAF1/CIP1) expression and induces S-phase entry in 12-O-tetradecanoylphorbol-13-acetate (TPA)-sensitive human cancer cells. Cell Growth Differ. 1999;10:223–30.PubMed
180.
Amundson SA, Zhan Q, Penn LZ, Fornace AJ. Myc suppresses induction of the growth arrest genes gadd34, gadd45, and gadd153 by DNA-damaging agents. Oncogene. 1998;17:2149–54.PubMedCrossRef
181.
Jin S, Tong T, Fan W, Fan F, Antinore MJ, Zhu X, et al. GADD45-induced cell cycle G2-M arrest associates with altered subcellular distribution of cyclin B1 and is independent of p38 kinase activity. Oncogene. 2002;21:8696–704.PubMedCrossRef
182.
183.
Möröy T, Saba I, Kosan C. The role of the transcription factor Miz-1 in lymphocyte development and lymphomagenesis—binding Myc makes the difference. In: Seminars in immunology; 2011. p. 379–87.
184.
Brenner C, Deplus R, Didelot C, Loriot A, Viré E, De Smet C, et al. Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO J. 2005;24:336–46.PubMedCrossRef
185.
Wong P-P, Miranda F, Chan KV, Berlato C, Hurst HC, Scibetta AG. Histone demethylase KDM5B collaborates with TFAP2C and myc to repress the cell cycle inhibitor p21cip (CDKN1A). Mol Cell Biol. 2012;32:1633–44.PubMedPubMedCentralCrossRef
186.
Gartel AL, Ye X, Goufman E, Shianov P, Hay N, Najmabadi F, et al. Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3. Proc Natl Acad Sci U S A. 2001;98:4510–5.PubMedPubMedCentralCrossRef
187.
Vaqué JP, Navascues J, Shiio Y, Laiho M, Ajenjo N, Mauleon I, et al. Myc antagonises Ras-mediated growth arrest in leukemia cells through the inhibition of the Ras-ERK-p21Cip1 pathway. J Biol Chem. 2005;280:1112–22.PubMedCrossRef
188.
189.
Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 down-regulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009;113:396–402.PubMedCrossRef
190.
Wong P, Iwasaki M, Somervaille TCP, Ficara F, Carico C, Arnold C, et al. The miR-17-92 microRNA polycistron regulates MLL leukemia stem cell potential by modulating p21 expression. Cancer Res. 2010;70:3833–42.PubMedPubMedCentralCrossRef
191.
Mateyak MK, Obaya AJ, Sedivy JM. c-Myc regulates cyclin D-Cdk4 and -Cdk6 activity but affects cell cycle progression at multiple independent points. Mol Cell Biol. 1999;19:4672–83.PubMedPubMedCentralCrossRef
192.
193.
Wu M, Bellas RE, Shen J, Yang W, Sonenshein GE. Increased p27Kip1 cyclin-dependent kinase inhibitor gene expression following anti-IgM treatment promotes apoptosis of WEHI 231 B cells. J Immunol. 1999;163(12):6530–35.
194.
Wu M, Arsura M, Bellas RE, FitzGerald MJ, Lee H, Schauer SL, et al. Inhibition of c-myc expression induces apoptosis of WEHI 231 murine B cells. Mol Cell Biol. 1996;16:5015–25.PubMedPubMedCentralCrossRef
195.
Yang W, Shen J, Wu M, Arsura M, FitzGerald M, Suldan Z, et al. Repression of transcription of the p27Kip1 cyclin-dependent kinase inhibitor gene by c-Myc. Oncogene. 2001;20:1688–702.PubMedCrossRef
196.
Chandramohan V, Mineva ND, Burke B, Jeay S, Wu M, Shen J, et al. c-Myc represses FOXO3a-mediated transcription of the gene encoding the p27Kip1 cyclin dependent kinase inhibitor. J Cell Biochem. 2008;104:2091–106.PubMedCrossRef
197.
Steiner P, Philipp A, Lukas J, Godden-Kent D, Pagano M, Mittnacht S, Bartek J, Eilers M. Identification of a Myc-dependent step during the formation of active G1 cyclin-cdk complexes. EMBO J. 1995;14(19):4814–26.
198.
Vlach J, Hennecke S, Alevizopoulos K, Conti D, Amati B. Growth arrest by the cyclin-dependent kinase inhibitor p27Kip1 is abrogated by c-Myc. EMBO J. 1996;15(23):6595–604.
199.
Soos TJ, Kiyokawa H, Yan JS, Rubin MS, Giordano A, DeBlasio A, Bottega S, Wong B, Mendelsohn J, Koff A. Formation of p27-CDK complexes during the human mitotic cell cycle. Cell Growth Differ. 1996;7(2):135–46.
200.
Obaya AJ, Sedivy JM. Regulation of cyclin-Cdk activity in mammalian cells. Cell Mol Life Sci. 2002;59:126–42.PubMedCrossRef
201.
Bretones G, Acosta JC, Caraballo JM, Ferrándiz N, Gómez-Casares MT, Albajar M, et al. SKP2 oncogene is a direct MYC target gene and MYC down-regulates p27 KIP1 through SKP2 in human leukemia cells. J Biol Chem. 2011;286:9815–25.PubMedPubMedCentralCrossRef
202.
Müller D, Bouchard C, Rudolph B, Steiner P, Stuckmann I, Saffrich R, et al. Cdk2-dependent phosphorylation of p27 facilitates its MSc-induced release from cyclin E/cdk2 complexes. Oncogene. 1997;15:2561–76.PubMedCrossRef
203.
O’Hagan RC, Ohh M, David G, De Alboran IM, Alt FW, Kaelin WG, et al. Myc-enhanced expression of Cul1 promotes ubiquitin-dependent proteolysis and cell cycle progression. Genes Dev. 2000;14:2185–91.PubMedPubMedCentralCrossRef
204.
Keller UB, Old JB, Dorsey FC, Nilsson JA, Nilsson L, MacLean KH, et al. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis. EMBO J. 2007;26:2562–74.PubMedPubMedCentralCrossRef
205.
Montagnoli A, Fiore F, Eytan E, Carrano AC, Draetta GF, Hershko A, et al. Ubiquitination of p27 is regulated by Cdk-dependent phosphorylation and trimeric complex formation. Genes Dev. 1999;13:1181–9.PubMedPubMedCentralCrossRef
206.
Sutterlüty H, Chatelain E, Marti A, Wirbelauer C, Senften M, Müller U, et al. p45SKP2 promotes p27Kip1 degradation and induces S phase in quiescent cells. Nat Cell Biol. 1999;1:207–14.PubMedCrossRef
207.
Blanco-Bose WE, Murphy MJ, Ehninger A, Offner S, Dubey C, Huang W, et al. c-Myc and its target foxM1 are critical downstream effectors of constitutive androstane receptor (CAR) mediated direct liver hyperplasia. Hepatology. 2008;48:1302–11.PubMedCrossRef
208.
Valovka T, Schönfeld M, Raffeiner P, Breuker K, Dunzendorfer-Matt T, Hartl M, et al. Transcriptional control of DNA replication licensing by Myc. Sci Rep. 2013;3:1–9.CrossRef
209.
Perna D, Fagà G, Verrecchia A, Gorski MM, Barozzi I, Narang V, et al. Genome-wide mapping of Myc binding and gene regulation in serum-stimulated fibroblasts. Oncogene. 2012;31:1695–709.PubMedCrossRef
210.
211.
Dominguez-Sola D, Ying CY, Grandori C, Ruggiero L, Chen B, Li M, et al. Non-transcriptional control of DNA replication by c-Myc. Nature. 2007;448:445–51.PubMedCrossRef
212.
Kops GJPL, Weaver BAA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer. 2005;5:773–85.PubMedCrossRef
213.
214.
Menssen A, Epanchintsev A, Rezaei N, Lodygin D, Jung P, Verdoodt B, et al. c-MYC delays prometaphase by direct transactivation of MAD2 and Bub R1: Identification of mechanisms underlying c-MYC-induced DNA damage and chromosomal instability. Cell Cycle. 2007;6:339–52.PubMedCrossRef
215.
Littler S, Sloss O, Geary B, Pierce A, Whetton AD, Taylor SS. Oncogenic MYC amplifies mitotic perturbations. Open Biol. 2019;9:109136.CrossRef
216.
Ciribilli Y, Singh P, Spanel R, Inga A, Borlak J. Decoding c-Myc networks of cell cycle and apoptosis regulated genes in a transgenic mouse model of papillary lung adenocarcinomas. Oncotarget. 2015;6:31569–92.PubMedPubMedCentralCrossRef
217.
Saito S, Liu X-F, Kamijo K, Raziuddin R, Tatsumoto T, Okamoto I, et al. Deregulation and mislocalization of the cytokinesis regulator ECT2 activate the rho signaling pathways leading to malignant transformation. J Biol Chem. 2004;279:7169–79.PubMedCrossRef
218.
Li Y, Pei J, Xia H, Ke H, Wang H, Tao W. Lats2, a putative tumor suppressor, inhibits G1/S transition. Oncogene. 2003;22:4398–405.PubMedCrossRef
219.
Yoon HS, Chen X, Yang VW. Krüppel-like factor 4 mediates p53-dependent G1/S cell cycle arrest in response to DNA damage. J Biol Chem. 2003;278:2101–5.PubMedCrossRef
220.
Huang Q, Raya A, DeJesus P, Chao SH, Quon KC, Caldwell JS, et al. Identification of p53 regulators by genome-wide functional analysis. Proc Natl Acad Sci U S A. 2004;101:3456–61.PubMedPubMedCentralCrossRef
221.
Del Sal G, Ruaro EM, Utrera R, Cole CN, Levine AJ, Schneider C. Gas1-induced growth suppression requires a transactivation-independent p53 function. Mol Cell Biol. 1995;15:7152–60.PubMedPubMedCentralCrossRef
222.
Wadhwa R, Yaguchi T, Hasan MK, Mitsui Y, Reddel RR, Kaul SC. Hsp70 family member, mot-2/mthsp70/GRP75, binds to the cytoplasmic sequestration domain of the p53 protein. Exp Cell Res. 2002;274:246–53.PubMedCrossRef
223.
Mei Y, Wu M. Noncoding RNAs regulating p53 and c-Myc signaling. Adv Exp Med Biol. 2016;927:337–65.PubMedCrossRef
224.
Bueno MJ, Malumbres M. MicroRNAs and the cell cycle. Biochim Biophys Acta Mol Basis Dis. 2011;1812:592–601.CrossRef
225.
Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K, Ovcharenko D, et al. The let-7 microRNA represses cell proliferation pathways in human cells. Cancer Res. 2007;67:7713–22.PubMedCrossRef
226.
227.
Chang TC, Yu D, Lee YS, Wentzel EA, Arking DE, West KM, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40:43–50.PubMedCrossRef
228.
Barsyte-Lovejoy D, Lau SK, Boutros PC, Khosravi F, Jurisica I, Andrulis IL, et al. The c-Myc oncogene directly induces the H19 noncoding RNA by allele-specific binding to potentiate tumorigenesis. Cancer Res. 2006;66:5330–7.PubMedCrossRef
229.
230.
Berteaux N, Lottin S, Monté D, Pinte S, Quatannens B, Coll J, et al. H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem. 2005;280:29625–36.PubMedCrossRef
231.
232.
Doose G, Haake A, Bernhart SH, López C, Duggimpudi S, Wojciech F, et al. MINCR is a MYC-induced lncRNA able to modulate MYC’s transcriptional network in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 2015;112:E5261–70.PubMedPubMedCentralCrossRef
233.
Popov N, Wanzel M, Madiredjo M, Zhang D, Beijersbergen R, Bernards R, et al. The ubiquitin-specific protease USP28 is required for MYC stability. Nat Cell Biol. 2007;9:765–74.PubMedCrossRef
234.
Bunch R, Povirk L, Orr M, et al. Influence of amsacrine (m-AMSA) on bulk and gene-specific DNA damage and c-myc expression in MCF-7 breast tumor cells. Biochem Pharmacol. 1994;47:317–29.PubMedCrossRef
235.
Fornari F Jr, Jarvis W, Grant S, et al. Growth arrest and non-apoptotic cell death associated with the suppression of c-myc expression in MCF-7 breast tumor cells following acute exposure to doxorubicin. Biochem Pharmacol. 1996;51:931–40.PubMedCrossRef
236.
Orr M, Fornari F, Randolph J, Biophysica DG-B, et al. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase 11 inhibitor, VM-26. Biochim Biophys Acta Gene Struct Expr. 1995;1262:139–45.CrossRef
237.
Watson NC, Di YM, Orr MS, Fornari J, Randolph JK, Magnet KJ, et al. Influence of ionizing radiation on proliferation, c-myc expression and the induction of apoptotic cell death in two breast tumour cell lines differing in p53 status. Int J Radiat Biol. 1997;72:547–59.PubMedCrossRef
238.
Magnet K, Orr M, et al. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells. Biochem Pharmacol. 2001;62:593–602.PubMedCrossRef
239.
Jain PT, Fornari FA, Randolph JK, Orr MS, Gewirtz DA. Induction of DNA damage, inhibition of DNA synthesis, and suppression of c-myc expression by the topoisomerase I inhibitor, camptothecin, in MCF-7 human breast tumor cells. Biochem Pharmacol. 1998;55:1263–9.PubMedCrossRef
240.
Orr M, Watson N, Sundaram S, et al. Ionizing radiation and teniposide increase p21waf1/cip1 and promote Rb dephosphorylation but fail to suppress E2F activity in MCF-7 breast tumor cells. ASPET. 1997;52:373–9.
241.
Gorrini C, Squatrito M, Luise C, Syed N. Tip60 is a haplo-insufficient tumour suppressor required for an oncogene-induced DNA damage response. Nature. 2007;448:1063–7.PubMedCrossRef
242.
Bassi C, Li YT, Khu K, Mateo F, Baniasadi PS, Elia A, et al. The acetyltransferase Tip60 contributes to mammary tumorigenesis by modulating DNA repair. Cell Death Differ. 2016;23:1198–208.PubMedPubMedCentralCrossRef
243.
Hughes H. Bax Is a Transcriptional Target and Mediator of c-Myc-induced Apoptosis 1. Cancer Res. 2000;60:6318–25.
244.
Barsyte-Lovejoy D, Mao D. c-Myc represses the proximal promoters of GADD45a and GADD153 by a post-RNA polymerase II recruitment mechanism. Oncogene. 2004;23:3481–6.PubMedCrossRef
245.
Rogulski K, Li Y, Rothermund K, Pu L, Watkins S, et al. Onzin, a c-Myc-repressed target, promotes survival and transformation by modulating the Akt–Mdm2–p53 pathway. Oncogene. 2005;24:7524–41.PubMedCrossRef
246.
Pusapati R, et al. ATM promotes apoptosis and suppresses tumorigenesis in response to Myc. Natl Acad Sci. 2006;103:1446–51.CrossRef
247.
Reimann M, Loddenkemper C, Rudolph C, Schildhauer I, Teichmann B, Stein H, et al. The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo. Blood J Am Soc Hematol. 2007;110:2996–3004.
248.
Guerra L, Albihn A, Tronnersjö S, Yan Q, Guidi R, Stenerlöw B, et al. Myc is required for activation of the ATM-dependent checkpoints in response to DNA damage. PLoS ONE. 2010;5:e8924.PubMedPubMedCentralCrossRef
249.
Chiang YC, Teng SC, Su YN, Hsieh FJ, Wu KJ. c-Myc directly regulates the transcription of the NBS1 gene involved in DNA double-strand break repair. J Biol Chem. 2003;278:19286–91.PubMedCrossRef
250.
Lee J. Direct activation of the ATM protein kinase by the Mre11/Rad50/Nbs1 complex. Science. 2004;304:93–6.PubMedCrossRef
251.
Lee J-H, Paull TT. ATM activation by DNA double-strand breaks through the Mre11-Rad50-Nbs1 complex. Science (80- ). 2005;308:551–4.CrossRef
252.
Herold S, Hock A, Herkert B, Berns K, Mullenders J, Beijersbergen R, et al. Miz1 and HectH9 regulate the stability of the checkpoint protein, TopBP1. EMBO J. 2008;27:2851–61.PubMedPubMedCentralCrossRef
253.
Vafa O, Wade M, Kern S, Beeche M, Pandita TK, Hampton GM, et al. c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability. Mol Cell. 2002;9:1031–44.PubMedCrossRef
254.
Hermeking H, Funk J, Reichert M, Ellwart J. Abrogation of p53-induced cell cycle arrest by c-Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene. 1995;11:1409–15.PubMed
255.
Seoane J, Le H. Myc suppression of the p21 Cip1 Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002;419:729–34.PubMedCrossRef
256.
257.
258.
259.
Karlsson A, Deb-Basu D. Defective double-strand DNA break repair and chromosomal translocations by MYC overexpression. Proc Natl Acad Sci. 2003;100:9974–9.PubMedPubMedCentralCrossRef
260.
Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-XL or Bcl-2 Is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21:5063–70.PubMedPubMedCentralCrossRef
261.
Gery S, Komatsu N, Baldjyan L, Yu A, Koo D, Koeffler HP. The circadian gene Per1 plays an important role in cell growth and DNA damage control in human cancer cells. Mol Cell. 2006;22:375–82.PubMedCrossRef
262.
Afanasyeva EA, Komarova EY, Larsson L-G, Bahram F, Margulis BA, Guzhova IV. Drug-induced Myc-mediated apoptosis of cancer cells is inhibited by stress protein Hsp70. Int J Cancer. 2007;121:2615–21.PubMedCrossRef
263.
Kennedy R, Quinn J. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659–68.PubMedCrossRef
264.
Quinn JE, et al. BRCA1 Functions as a Differential Modulator of Chemotherapy-induced Apoptosis. Cancer Res. 2003;63:6221–8.PubMed
265.
Kennedy RD, Gorski JJ, Quinn JE, Stewart GE, James CR, Moore S, et al. BRCA1 and c-Myc associate to transcriptionally repress psoriasin, a DNA damage-inducible gene. Cancer Res. 2005;65:10265–72.PubMedCrossRef
266.
Albihn A, Lovén J, Ohlsson J, Osorio LM, Henriksson M. c-Myc-dependent etoposide-induced apoptosis involves activation of bax and caspases, and PKCdelta signaling. J Cell Biochem. 2006;98:1597–614.PubMedCrossRef
267.
Albihn A, Mo H, Yang Y, Henriksson M. Camptothecin-induced apoptosis is enhanced by Myc and involves PKCdelta signaling. Int J Cancer. 2007;121:1821–9.PubMedCrossRef
268.
Maclean KH, Keller UB, Rodriguez-Galindo C, Nilsson JA, Cleveland JL. c-Myc augments gamma irradiation-induced apoptosis by suppressing Bcl-X L. Mol Cell Biol. 2003;23:7256–70.PubMedPubMedCentralCrossRef
269.
Arango D, Mariadason J, Wilson A. c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. Br J Cancer. 2003;89:1757–65.PubMedPubMedCentralCrossRef
270.
Supino R, Perego P, Gatti L. A role for c-myc in DNA damage-induced apoptosis in a human TP53-mutant small-cell lung cancer cell line. Eur J Cancer. 2001;37:2247–56.PubMedCrossRef
271.
Ohga T, Koike K, Ono M, Makino Y, Itagaki Y, Tanimoto M, et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res. 1996;56:4224–8.PubMed
272.
Koike K, Uchiumi T, Ohga T, Toh S, Wada M, et al. Nuclear translocation of the Y-box binding protein by ultraviolet irradiation. FEBS Lett. 1997;417:390–4.PubMedCrossRef
273.
Ise T, Nagatani G, Imamura T, et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res. 1999;59:342–6.PubMed
274.
Uramoto H, Izumi H, Ise T, Tada M, Uchiumi T, Kuwano M, et al. p73 interacts with c-Myc to regulate Y-box-binding protein-1 expression*. J Biol Chem. 2002;277:31694–702.PubMedCrossRef
275.
Dubrez L, Goldwasser F, Genne P. The role of cell cycle regulation and apoptosis triggering in determining the sensitivity of leukemic cells to topoisomerase I and II inhibitors. Leukemia. 1995;9:1013–24.PubMed
276.
Adachi S, Obaya AJ, Han Z, Ramos-Desimone N, Wyche JH, Sedivy JM. c-Myc is necessary for DNA damage-induced apoptosis in the G2 phase of the cell cycle. Mol Cell Biol. 2001;21:4929–37.PubMedPubMedCentralCrossRef
277.
Luoto KR, Meng AX, Wasylishen AR, Zhao H, Coackley CL, Penn LZ, et al. Tumor cell kill by c-MYC depletion: role of MYC-regulated genes that control DNA double-strand break repair. Cancer Res. 2010;70:8748–59.PubMedCrossRef
278.
Cui F, Fan R, Chen Q, He Y, Song M, Shang Z, et al. The involvement of c-Myc in the DNA double-strand break repair via regulating radiation-induced phosphorylation of ATM and DNA-PKcs activity. Mol Cell Biochem. 2015;406:43–51.PubMedCrossRef
279.
Gordan JD, Lal P, Dondeti VR, Letrero R, Parekh KN, Oquendo CE, et al. HIF-α effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell. 2008;14:435–46.PubMedPubMedCentralCrossRef
280.
Eischen CM, Weber JD, Roussel MF, Sherr CJ, Cleveland JL. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis. Genes Dev. 1999;13:2658–69.PubMedPubMedCentralCrossRef
281.
Schmitt CA, McCurrach ME, De Stanchina E, Wallace-Brodeur RR, Lowe SW. INK4a/ARF mutations accelerate lymphomagenesis and promote chemoresistance by disabling p53. Genes Dev. 1999;13:2670–7.PubMedPubMedCentralCrossRef
282.
Phesse TJ, Myant KB, Cole AM, Ridgway RA, Pearson H, Muncan V, et al. Endogenous c-Myc is essential for p53-induced apoptosis in response to DNA damage in vivo. Cell Death Differ. 2014;21:956–66.PubMedPubMedCentralCrossRef
283.
Yu Q, He M, Lee NH, Liu ET. Identification of Myc-mediated death response pathways by microarray analysis. J Biol Chem. 2002;277:13059–66.PubMedCrossRef
284.
Ho JSL, Ma W, Mao DYL, Benchimol S. p53-dependent transcriptional repression of c-myc is required for G1 cell cycle arrest. Mol Cell Biol. 2005;25:7423–31.PubMedPubMedCentralCrossRef
285.
Sutcliffe T, Fu L, Abraham J, et al. A functional wild-type p53 gene is expressed in human acute myeloid leukemia cell lines. Am Soc Hematol. 1998;92:2977–9.
286.
Zhang T, Brazhnik P, Tyson JJ. Exploring mechanisms of the DNA-damage response: p53 pulses and their possible relevance to apoptosis. Cell Cycle. 2007;6:85–94.PubMedCrossRef
287.
Bar-Or RL, Maya R, Segel LA, Alon U, Levine AJ, Oren M. Generation of oscillations by the p53-Mdm2 feedback loop: a theoretical and experimental study. Proc Natl Acad Sci U S A. 2000;97:11250–5.CrossRef
288.
Ma L, Wagner J, Rice JJ, Hu W, Levine AJ, Stolovitzky GA. A plausible model for the digital response of p53 to DNA damage. Proc Natl Acad Sci U S A. 2005;102:14266–71.PubMedPubMedCentralCrossRef
289.
Porter JR, Fisher BE, Batchelor E. P53 pulses diversify target gene expression dynamics in an mRNA half-life-dependent manner and delineate co-regulated target gene subnetworks. Cell Syst. 2016;2:272–82.PubMedPubMedCentralCrossRef
290.
Porter JR, Fisher BE, Baranello L, Liu JC, Kambach DM, Nie Z, et al. Global inhibition with specific activation: how p53 and MYC redistribute the transcriptome in the DNA double-strand break response. Mol Cell. 2017;67:1013-1025.e9.PubMedPubMedCentralCrossRef
291.
Moberg KH, Tyndall WA, Hall DJ. Wild-type murine p53 represses transcription from the murinec-myc promoter in a human glial cell line. J Cell Biochem. 1992;49:208–15.PubMedCrossRef
292.
Levy N, Yonish-Rouach E, Oren M, Kimchi A. Complementation by wild-type p53 of interleukin-6 effects on M1 cells: induction of cell cycle exit and cooperativity with c-myc suppression. Mol Cell Biol. 1993;13:7942–52.PubMedPubMedCentral
293.
Lin CY, Lovén J, Rahl PB, Paranal RM, Burge CB, Bradner JE, et al. Transcriptional amplification in tumor cells with elevated c-Myc. Cell. 2012;151:56–67.PubMedPubMedCentralCrossRef
294.
Hyeon HK, Kuwano Y, Srikantan S, Eun KL, Martindale JL, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009;23:1743–8.CrossRef
295.
Sachdeva M, Zhu S, Wu F, Wu H, Walia V, Kumar S, et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc Natl Acad Sci U S A. 2009;106:3207–12.PubMedPubMedCentralCrossRef
296.
Challagundla KB, Sun X-X, Zhang X, DeVine T, Zhang Q, Sears RC, et al. Ribosomal protein L11 recruits miR-24/miRISC to repress c-Myc expression in response to ribosomal stress. Mol Cell Biol. 2011;31:4007–21.PubMedPubMedCentralCrossRef
297.
Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell. 2007;26:745–52.PubMedPubMedCentralCrossRef
298.
Corney DC, Flesken-Nikitin A, Godwin AK, Wang W, Nikitin AY. MicroRNA-34b and MicroRNA-34c are targets of p53 and cooperate in control of cell proliferation and adhesion-independent growth. Cancer Res. 2007;67:8433–8.PubMedCrossRef
299.
300.
Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E, et al. Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res. 2008;68:3193–203.PubMedPubMedCentralCrossRef
301.
Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A, et al. Differential regulation of microRNAs by p53 revealed by massively parallel sequencing: miR-34a is a p53 target that induces apoptosis and G 1-arrest. Cell Cycle. 2007;6:1586–93.PubMedCrossRef
302.
Yi WK, Cannell IG, De Moor CH, Hill K, Garside PG, Hamilton TL, et al. The mechanism of micro-RNA-mediated translation repression is determined by the promoter of the target gene. Proc Natl Acad Sci U S A. 2008;105:8866–71.CrossRef
303.
Lujambio A, Calin GA, Villanueva A, Ropero S, Sánchez-Céspedes M, Blanco D, et al. A microRNA DNA methylation signature for human cancer metastasis. Proc Natl Acad Sci U S A. 2008;105:13556–61.PubMedPubMedCentralCrossRef
304.
Li Y, Challagundla KB, Sun XX, Zhang Q, Dai MS. MicroRNA-130a associates with ribosomal protein L11 to suppress c-Myc expression in response to UV irradiation. Oncotarget. 2015;6:1101–14.PubMedCrossRef
305.
Sakamuro D, Elliott KJ, Wechsler-Reya R, Prendergast GC. BIN1 is a novel MYC-interacting protein with features of a tumour suppressor. Nat Genet. 1996;14:69–77.PubMedCrossRef
306.
Cassimere EK, Pyndiah S, Sakamuro D. The c-MYC-interacting proapoptotic tumor suppressor BIN1 is a transcriptional target for E2F1 in response to DNA damage. Cell Death Differ. 2009;16:1641–53.PubMedCrossRef
307.
Elliott K, Sakamuro D, Basu A, Du W, Wunner W, Staller P, et al. Bin1 functionally interacts with Myc and inhibits cell proliferation via multiple mechanisms. Oncogene. 1999;18:3564–73.PubMedCrossRef
308.
Kinney EL, Tanida S, Rodrigue AA, Johnson JK, Tompkins VS, Sakamuro D. Adenovirus E1A oncoprotein liberates c-Myc activity to promote cell proliferation through abating Bin1 expression via an Rb/E2F1-dependent mechanism. J Cell Physiol. 2008;216:621–31.PubMedCrossRef
309.
Pyndiah S, Tanida S, Ahmed KM, Cassimere EK, Choe C, Sakamuro D. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance. Sci Signal. 2011;4:r19.CrossRef
310.
Meyer-Ficca ML, Meyer RG, Jacobson EL, Jacobson MK. Poly(ADP-ribose) polymerases: managing genome stability. Int J Biochem Cell Biol. 2005;37:920–6.PubMedCrossRef
311.
El-Khamisy SF, Masutani M, Suzuki H, Caldecott KW. A requirement for PARP-1 for the assembly or stability of XRCC1 nuclear foci at sites of oxidative DNA damage. Nucleic Acids Res. 2003;31:5526–33.PubMedPubMedCentralCrossRef
312.
Masson M, Niedergang C, Schreiber V, Muller S, Menissier-de Murcia J, de Murcia G. XRCC1 is specifically associated with poly(ADP-ribose) polymerase and negatively regulates its activity following DNA damage. Mol Cell Biol. 1998;18:3563–71.PubMedPubMedCentralCrossRef
313.
Prendergast GC. Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene. 2008;27:3889–900.PubMedCrossRef
314.
Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med. 2005;11:312–9.PubMedCrossRef
315.
Kim MY, Zhang T, Kraus WL. Poly(ADP-ribosyl)ation by PARP-1: “PAR-laying” NAD+ into a nuclear signal. Genes Dev. 2005;19:1951–67.PubMedCrossRef
316.
Di Fagagna FDA, Hande MP, Tong WM, Lansdorp PM, Wang ZQ, Jackson SP. Functions of poly(ADP-ribose) polymerase in controlling telomere length and chromosomal stability. Nat Genet. 1999;23:76–80.CrossRef
317.
Ramalingam A, Farmer GE, Stamato TD, Prendergast GC. Bin1 interacts with and restrains the DNA end-binding protein complex Ku. Cell Cycle. 2007;6:1914–8.PubMedCrossRef
318.
Chen LL, Lin HP, Zhou WJ, He CX, Zhang ZY, Cheng ZL, et al. SNIP1 recruits TET2 to regulate c-MYC target genes and cellular DNA damage response. Cell Rep. 2018;25:1485.e4-1500.e4.CrossRef
319.
Roche KC, Wiechens N, Owen-Hughes T, Perkins ND. The FHA domain protein SNIP1 is a regulator of the cell cycle and cyclin D1 expression. Oncogene. 2004;23:8185–95.PubMedCrossRef
320.
Roche KC, Rocha S, Bracken CP, Perkins ND. Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1. Oncogene. 2007;26:4523–30.PubMedCrossRef
321.
Felix K, Polack A, Pretsch W, Jackson SH, Feigenbaum L, Bornkamm GW, et al. Moderate hypermutability of a transgenic lacZ reporter gene in Myc-dependent inflammation-induced plasma cell tumors in mice. Cancer Res. 2004;64:530–7.PubMedCrossRef
322.
Taylor C, Mai S. c-Myc-associated genomic instability of the dihydrofolate reductase locus in vivo. Cancer Detect Prev. 1998;22:350–6.PubMedCrossRef
323.
324.
Ray S, Atkuri KR, Deb-Basu D, Adler AS, Chang HY, Herzenberg LA, et al. MYC can induce DNA breaks in vivo and in vitro independent of reactive oxygen species. Cancer Res. 2006;66:6598–605.PubMedCrossRef
325.
Dang CV, Li F, Lee LA. Could MYC induction of mitochondrial biogenesis be linked to ROS production and genomic instability? Cell Cycle. 2005;4:1465–6.PubMedCrossRef
326.
Wade M, Wahl GM. c-Myc, genome instability, and tumorigenesis: the devil is in the details. Curr Top Microbiol Immunol. 2006;302:169–203.PubMed
327.
Gorgoulis VG, Vassiliou LVF, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, et al. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature. 2005;434:907–13.PubMedCrossRef
328.
Classon M, Henriksson M, Sümegi J, Klein G, Hammaskjöld ML. Elevated c-myc expression facilitates the replication of SV40 DNA in human lymphoma cells. Nature. 1987;330:272–4.PubMedCrossRef
329.
330.
Nishitani H, Lygerou Z, Nishimoto T, Nurse P. The Cdt1 protein is required to license DNA for replication in fission yeast. Nature. 2000;404:625–8.PubMedCrossRef
331.
Hofmann JF, Beach D. cdt1 is an essential target of the Cdc10/Sct1 transcription factor: requirement for DNA replication and inhibition of mitosis. EMBO J. 1994;13:425–34.PubMedPubMedCentralCrossRef
332.
Maiorano D, Moreau J, Méchali M. XCDT1 is required for the assembly of pre-replicative complexes in Xenopus laevis. Nature. 2000;404:622–5.PubMedCrossRef
333.
Kurashima K, Sekimoto T, Oda T, Kawabata T, Hanaoka F, Yamashita T. Polη, a Y-family translesion synthesis polymerase, promotes cellular tolerance of Myc-induced replication stress. J Cell Sci. 2018;131:jcs212183.PubMedCrossRef
334.
Kolli S, Buchmann AM, Williams J, Weitzman S, Thimmapaya B. Antisense-mediated depletion of p300 in human cells leads to premature exit and up-regulation of c-MYC. Proc Natl Acad Sci U S A. 2001;98:4646–51.PubMedPubMedCentralCrossRef
335.
Rajabi HN, Baluchamy S, Kolli S, Nag A, Srinivas R, Raychaudhuri P, et al. Effects of depletion of CREB-binding protein on c-Myc regulation and cell cycle G1-S transition. J Biol Chem. 2005;280:361–74.PubMedCrossRef
336.
Sankar N, Kadeppagari RK, Thimmapaya B. c-Myc-induced aberrant DNA synthesis and activation of DNA damage response in p300 knockdown cells. J Biol Chem. 2009;284:15193–205.PubMedPubMedCentralCrossRef
337.
Song L, Dai T, Xie Y, Wang C, Lin C, Wu Z, et al. Up-regulation of miR-1245 by c-myc targets BRCA2 and impairs DNA repair. J Mol Cell Biol. 2012;4:108–17.PubMedCrossRef
338.
Li Z, Owonikoko TK, Sun SY, Ramalingam SS, Doetsch PW, Xiao ZQ, et al. c-Myc suppression of DNA double-strand break repair. Neoplasia (United States). 2012;14:1190–202.CrossRef
339.
Mao DYL, Watson JD, Yan PS, Barsyte-Lovejoy D, Khosravi F, Wei-Lynn Wong W, et al. Analysis of MYC bound loci identified by CpG island arrays shows that Max is essential for MYC-dependent repression. Curr Biol. 2003;13:882–6.PubMedCrossRef
340.
Sallmyr A, Fan J, Rassool FV. Genomic instability in myeloid malignancies: increased reactive oxygen species (ROS), DNA double strand breaks (DSBs) and error-prone repair. Cancer Lett. 2008;270:1–9.PubMedCrossRef
341.
Muvarak N, Nagaria P, Rassool FV. Genomic instability in chronic myeloid leukemia: targets for therapy? Curr Hematol Malig Rep. 2012;7:94–102.PubMedCrossRef
342.
Muvarak N, Kelley S, Robert C, Baer MR, Perrotti D, Gambacorti-Passerini C, et al. C-MYC generates repair errors via increased transcription of alternative-NHEJ factors, LIG3 and PARP1, in tyrosine kinase-activated leukemias. Mol Cancer Res. 2015;13:699–712.PubMedPubMedCentralCrossRef
343.
Fan J, Li L, Small D, Rassool F. Cells expressing FLT3/ITD mutations exhibit elevated repair errors generated through alternative NHEJ pathways: implications for genomic instability and therapy. Blood J Am Soc Hematol. 2010;116:5298–305.
344.
Li L, Robert C, Rassool VF. The role of error-prone alternative non-homologous end-joining in genomic instability in cancer. Rijeka: InTech; 2011.CrossRef
345.
Jin Z, May WS, Gao F, Flagg T, Deng X. Bcl2 suppresses DNA repair by enhancing c-Myc transcriptional activity. J Biol Chem. 2006;281:14446–56.PubMedCrossRef
346.
Partlin MM, Homer E, Robinson H, McCormick CJ, Crouch DH, Durant ST, et al. Interactions of the DNA mismatch repair proteins MLH1 and MSH2 with c-MYC and MAX. Oncogene. 2003;22:819–25.CrossRef
347.
Bucci B, D’Agnano I, Amendola D, Citti A, Raza GH, Miceli R, et al. Myc down-regulation sensitizes melanoma cells to radiotherapy by inhibiting MLH1 and MSH2 mismatch repair proteins. Clin Cancer Res. 2005;11:2756–67.PubMedCrossRef
348.
349.
350.
Candé C, Cecconi F, Dessen P, Kroemer G. Apoptosis-inducing factor (AIF): key to the conserved caspase-independent pathways of cell death? J Cell Sci. 2002;115:4727–34.PubMedCrossRef
351.
Brentnall M, Rodriguez-Menocal L, De Guevara RL, Cepero E, Boise LH. Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol. 2013;14:32.PubMedPubMedCentralCrossRef
352.
Kale J, Osterlund EJ, Andrews DW. BCL-2 family proteins: changing partners in the dance towards death. Cell Death Differ. 2018;25:65–80.PubMedCrossRef
353.
O’Neill KL, Huang K, Zhang J, Chen Y, Luo X. Inactivation of prosurvival Bcl-2 proteins activates Bax/Bak through the outer mitochondrial membrane. Genes Dev. 2016;30:973–88.PubMedPubMedCentralCrossRef
354.
Gross A, McDonnell JM, Korsmeyer SJ. BCL-2 family members and the mitochondria in apoptosis. Genes Dev. 1999;13:1899–911.PubMedCrossRef
355.
356.
357.
358.
Schleich K, Buchbinder JH, Pietkiewicz S, Kähne T, Warnken U, Öztürk S, et al. Molecular architecture of the DED chains at the DISC: regulation of procaspase-8 activation by short DED proteins c-FLIP and procaspase-8 prodomain. Cell Death Differ. 2016;23:681–94.PubMedCrossRef
359.
Li H, Zhu H, Xu CJ, Yuan J. Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell. 1998;94:491–501.CrossRefPubMed
360.
Gross A, Yin XM, Wang K, Wei MC, Jockel J, Milliman C, et al. Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death. J Biol Chem. 1999;274:1156–63.PubMedCrossRef
361.
Hughes MA, Powley IR, Jukes-Jones R, Horn S, Feoktistova M, Fairall L, et al. Co-operative and hierarchical binding of c-FLIP and caspase-8: a unified model defines how c-FLIP isoforms differentially control cell fate. Mol Cell. 2016;61:834–49.PubMedPubMedCentralCrossRef
362.
Juin P, Hueber AO, Littlewood T, Evan G. c-Myc-induced sensitization to apoptosis is mediated through cytochrome c release. Genes Dev. 1999;13:1367–81.PubMedPubMedCentralCrossRef
363.
Mitchell KO, Ricci MS, Miyashita T, Dicker DT, Jin Z, Reed JC, et al. Bax is a transcriptional target and mediator of c-myc-induced apoptosis. Cancer Res. 2000;60:6318–25.PubMed
364.
Cao X, Bennett RL, May WS. c-Myc and caspase-2 are involved in activating Bax during cytotoxic drug-induced apoptosis. J Biol Chem. 2008;283:14490–6.PubMedPubMedCentralCrossRef
365.
Juin P, Hunt A, Littlewood T, Griffiths B, Swigart LB, Korsmeyer S, et al. c-Myc functionally cooperates with Bax to induce apoptosis. Mol Cell Biol. 2002;22:6158–69.PubMedPubMedCentralCrossRef
366.
Nieminen AI, Eskelinen VM, Haikala HM, Tervonen TA, Yan Y, Partanen JI, et al. Myc-induced AMPK-phospho p53 pathway activates Bak to sensitize mitochondrial apoptosis. Proc Natl Acad Sci U S A. 2013;110:E1839–48.PubMedPubMedCentralCrossRef
367.
Eischen CM, Woo D, Roussel MF, Cleveland JL. Apoptosis triggered by Myc-induced suppression of Bcl-X(L) or Bcl-2 is bypassed during lymphomagenesis. Mol Cell Biol. 2001;21:5063–70.PubMedPubMedCentralCrossRef
368.
Hueber AO, Zörnig M, Lyon D, Suda T, Nagata S, Evan GI. Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis. Science (80- ). 1997;278:1305–9.CrossRef
369.
Klefstrom J, Västrik I, Saksela E, Valle J, Eilers M, Alitalo K. c-Myc induces cellular susceptibility to the cytotoxic action of TNF-alpha. EMBO J. 1994;13:5442–50.PubMedPubMedCentralCrossRef
370.
Klefstrom J, Arighi E, Littlewood T, Jäättelä M, Saksela E, Evan GI, et al. Induction of TNF-sensitive cellular phenotype by c-Myc involves p53 and impaired NF-kappaB activation. EMBO J. 1997;16:7382–92.PubMedPubMedCentralCrossRef
371.
Nilsson JA, Cleveland JL. Myc pathways provoking cell suicide and cancer. Oncogene. 2003;22:9007–21.PubMedCrossRef
372.
Sayyadi M, Safaroghli-Azar A, Safa M, Abolghasemi H, Momeny M, Bashash D. NF-κB-dependent mechanism of action of c-Myc inhibitor 10058–F4: highlighting a promising effect of c-Myc inhibition in Leukemia cells, irrespective of p53 status. Iran J Pharm Res. 2020;19:153.PubMedPubMedCentral
373.
Klefstrom J, Verschuren EW, Evan G. c-Myc augments the apoptotic activity of cytosolic death receptor signaling proteins by engaging the mitochondrial apoptotic pathway. J Biol Chem. 2002;277:43224–32.PubMedCrossRef
374.
Järvinen K, Hotti A, Santos L, Nummela P, Hölttä E. Caspase-8, c-FLIP, and caspase-9 in c-Myc-induced apoptosis of fibroblasts. Exp Cell Res. 2011;317:2602–15.PubMedCrossRef
375.
Brunner T, Kasibhatla S, Pinkoski MJ, Frutschi C, Yoo NJ, Echeverri F, et al. Expression of Fas ligand in activated T cells is regulated by c-Myc. J Biol Chem. 2000;275:9767–72.PubMedCrossRef
376.
Haupt S, Berger M, Goldberg Z, Haupt Y. Apoptosis: the p53 network. J Cell Sci. 2003;116:4077–85.PubMedCrossRef
377.
Zhao R, Gish K, Murphy M, Yin Y, Notterman D, Hoffman WH, et al. The transcriptional program following p53 activation. In: Cold spring harbor symposia quantitative biology. 2000; vol. 65, p. 475–82.
378.
Bossi G, Lapi E, Strano S, Rinaldo C, Blandino G, Sacchi A. Mutant p53 gain of function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 expression. Oncogene. 2006;25:304–9.PubMedCrossRef
379.
Wawryk-Gawda E, Chylińska-Wrzos P, Lis-Sochocka M, Chłapek K, Bulak K, Jędrych M, et al. P53 protein in proliferation, repair and apoptosis of cells. Protoplasma. 2014;251:525–33.PubMedCrossRef
380.
Geyer RK, Yu ZK, Maki CG. The MDM2 RING-finger domain is required to promote p53 nuclear export. Nat Cell Biol. 2000;2:569–73.PubMedCrossRef
381.
Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, et al. Myc signaling via the ARF tumor suppressor regulates p53-dependent apoptosis and immortalization. Genes Dev. 1998;12:2424–33.PubMedPubMedCentralCrossRef
382.
Chipuk JE, Kuwana T, Bouchier-Hayes L, Droin NM, Newmeyer DD, Schuler M, et al. Direct activation of Bax by p53 mediates mitochondrial membrane permeabilization and apoptosis. Science (80- ). 2004;303:1010–4.CrossRef
383.
Leu JI, Dumont P, Hafey M, Murphy ME, George DL. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat Cell Biol. 2004;6:443–50.PubMedCrossRef
384.
Blyth K, Stewart M, Bell M, James C, Evan G, Neil JC, et al. Sensitivity to myc-induced apoptosis is retained in spontaneous and transplanted lymphomas of CD2-mycERTM mice. Oncogene. 2000;19:773–82.PubMedCrossRef
385.
Raveh T, Droguett G, Horwitz MS, DePinho RA, Kimchi A. DAP kinase activates a p19ARF/p53-mediated apoptotic checkpoint to suppress oncogenic transformation. Nat Cell Biol. 2001;3:1–7.PubMedCrossRef
386.
Raveh T, Kimchi A. DAP kinase-a proapoptotic gene that functions as a tumor suppressor. Exp Cell Res. 2001;264:185–92.PubMedCrossRef
387.
Redza-Dutordoir M, Averill-Bates DA. Activation of apoptosis signalling pathways by reactive oxygen species. Biochim Biophys Acta Mol Cell Res. 2016;1863:2977–92.CrossRef
388.
Tanaka H, Matsumura I, Ezoe S, Satoh Y, Sakamaki T, Albanese C, et al. E2F1 and c-Myc potentiate apoptosis through inhibition of NF-kappaB activity that facilitates MnSOD-mediated ROS elimination. Mol Cell. 2002;9:1017–29.PubMedCrossRef
389.
Packham G, Cleveland JL. Ornithine decarboxylase is a mediator of c-Myc-induced apoptosis. Mol Cell Biol. 1994;14:5741–7.PubMedPubMedCentral
390.
Chandramohan V, Jeay S, Pianetti S, Sonenshein GE. Reciprocal control of forkhead box O 3a and c-Myc via the phosphatidylinositol 3-kinase pathway coordinately regulates p27 Kip1 levels. J Immunol. 2004;172:5522–7.PubMedCrossRef
391.
392.
Delpuech O, Griffiths B, East P, Essafi A, Lam EW-F, Burgering B, et al. Induction of Mxi1-SRα by FOXO3a contributes to repression of Myc-dependent gene expression. Mol Cell Biol. 2007;27:4917–30.PubMedPubMedCentralCrossRef
393.
Gan B, Lim C, Chu G, Hua S, Ding Z, Collins M, et al. FoxOs enforce a progression checkpoint to constrain mTORC1-activated renal tumorigenesis. Cancer Cell. 2010;18:472–84.PubMedPubMedCentralCrossRef
394.
Amente S, Zhang J, Lubrano Lavadera M, Lania L, Avvedimento EV, Majello B. Myc and PI3K/AKT signaling cooperatively repress FOXO3a-dependent PUMA and GADD45a gene expression. Nucleic Acids Res. 2011;39:9498–507.PubMedPubMedCentralCrossRef
395.
Hamanaka RB, Chandel NS. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem Sci. 2010;35:505–13.PubMedPubMedCentralCrossRef
396.
Jensen KS, Binderup T, Jensen KT, Therkelsen I, Borup R, Nilsson E, et al. FoxO3A promotes metabolic adaptation to hypoxia by antagonizing Myc function. EMBO J. 2011;30:4554–70.PubMedPubMedCentralCrossRef
397.
Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A. FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ. 2012;19:968–79.PubMedCrossRef
398.
Fernandez-Vidal A, Mazars A, Manenti S. CDC25A: a rebel within the CDC25 phosphatases family? Anticancer Agents Med Chem. 2008;8:825–31.PubMedCrossRef
399.
Kagaya S, Kitanaka C, Noguchi K, Mochizuki T, Sugiyama A, Asai A, et al. A functional role for death proteases in s-Myc- and c-Myc-mediated apoptosis. Mol Cell Biol. 1997;17:6736–45.PubMedPubMedCentralCrossRef
400.
401.
Zhang Y, Wang Z, Li X, Magnuson NS. Pim kinase-dependent inhibition of c-Myc degradation. Oncogene. 2008;27:4809–4570.PubMedCrossRef
402.
Mochizuki T, Kitanaka C, Noguchi K, Muramatsu T, Asai A, Kuchino Y. Physical and functional interactions between Pim-1 kinase and Cdc25A phosphatase. Implications for the Pim-1-mediated activation of the c-Myc signaling pathway. J Biol Chem. 1999;274:18659–66.PubMedCrossRef
403.
Jagannathan-Bogdan M, Zon LI. Hematopoiesis. Development. 2013;12:2463–7.CrossRef
404.
Kondo M, Wagers AJ, Manz MG, Prohaska SS, Scherer DC, Beilhack GF, et al. Biology of hematopoietic stem cells and progenitors: implications for clinical application. Annu Rev Immunol. 2003;21:759–806.PubMedCrossRef
405.
406.
Reavie L, Della GG, Crusio K, Aranda-Orgilles B, Buckley SM, Thompson B, et al. Regulation of hematopoietic stem cell differentiation by a single ubiquitin ligase-substrate complex. Nat Immunol. 2010;11:207–15.PubMedPubMedCentralCrossRef
407.
Wilson A, Murphy MJ, Oskarsson T, Kaloulis K, Bettess MD, Oser GM, et al. c-Myc controls the balance between hematopoietic stem cell self-renewal and differentiation. Genes Dev. 2004;18:2747–63.PubMedPubMedCentralCrossRef
408.
409.
Huang CY, Bredemeyer AL, Walker LM, Bassing CH, Sleckman BP. Dynamic regulation of c-Myc proto-oncogene expression during lymphocyte development revealed by a GFP-c-Myc knock-in mouse. Eur J Immunol. 2008;38:342–9.PubMedCrossRef
410.
Sanders JA, Schorl C, Patel A, Sedivy JM, Gruppuso PA. Postnatal liver growth and regeneration are independent of c-myc in a mouse model of conditional hepatic c-myc deletion. BMC Physiol. 2012;12:1–15.PubMedPubMedCentralCrossRef
411.
Morrison SJ, Hemmati HD, Wandycz AM, Weissman IL. The purification and characterization of fetal liver hematopoietic stem cells. Proc Natl Acad Sci U S A. 1995;92:10302–6.PubMedPubMedCentralCrossRef
412.
Acosta JC, Ferrándiz N, Bretones G, Torrano V, Blanco R, Richard C, et al. Myc inhibits p27-induced erythroid differentiation of leukemia cells by repressing erythroid master genes without reversing p27-mediated cell cycle arrest. Mol Cell Biol. 2008;28:7286–95.PubMedPubMedCentralCrossRef
413.
Dose M, Khan I, Guo Z, Kovalovsky D, Krueger A, Von Boehmer H, et al. c-Myc mediates pre-TCR-induced proliferation but not developmental progression. Blood. 2006;108:2669–77.PubMedPubMedCentralCrossRef
414.
Klemsz MJ, Justement LB, Palmer E, Cambier JC. Induction of c-fos and c-myc expression during B cell activation by IL-4 and immunoglobulin binding ligands. J Immunol. 1989;143:1032–9.PubMedCrossRef
415.
Larsson LG, Schena M, Carlsson M, Sallstrom J, Nilsson K. Expression of the c-myc protein is down-regulated at the terminal stages during in vitro differentiation of B-type chronic lymphocytic leukemia cells. Blood. 1991;77:1025–32.PubMedCrossRef
416.
417.
Preston GC, Sinclair LV, Kaskar A, Hukelmann JL, Navarro MN, Ferrero I, et al. Single cell tuning of Myc expression by antigen receptor signal strength and interleukin-2 in T lymphocytes. EMBO J. 2015;34:2008–24.PubMedPubMedCentralCrossRef
418.
Habib T, Park H, Tsang M, De Alborán IM, Nicks A, Wilson L, et al. Myc stimulates B lymphocyte differentiation and amplifies calcium signaling. J Cell Biol. 2007;179:717–31.PubMedPubMedCentralCrossRef
419.
Delgado MD, Albajar M, Gomez-Casares MT, Batlle A, León J. MYC oncogene in myeloid neoplasias. Clin Transl Oncol. 2013;15:87–94.PubMedCrossRef
420.
Guo Y, Niu C, Breslin P, Tang M, Zhang S, Wei W, et al. c-Myc-mediated control of cell fate in megakaryocyte-erythrocyte progenitors. Blood. 2009;114:2097–106.PubMedPubMedCentralCrossRef
421.
Adams JM, Harris AW, Pinkert CA, Corcoran LM, Alexander WS, Cory S, et al. The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice. Nature. 1985;318:533–8.PubMedCrossRef
422.
Schmidt EV, Pattengale PK, Weir L, Leder P. Transgenic mice bearing the human c-myc gene activated by an immunoglobulin enhancer: a pre-B-cell lymphoma model. Proc Natl Acad Sci U S A. 1988;85:6047–51.PubMedPubMedCentralCrossRef
423.
Langdon WY, Harris AW, Cory S, Adams JM. The c-myc oncogene perturbs B lymphocyte development in Eμ-myc transgenic mice. Cell. 1986;47:11–8.PubMedCrossRef
424.
Schmitt CA, Fridman JS, Yang M, Baranov E, Hoffman RM, Lowe SW. Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 2002;1:289–98.PubMedCrossRef
425.
Felsher DW, Bishop JM. Reversible tumorigenesis by MYC in hematopoietic lineages. Mol Cell. 1999;4:199–207.PubMedCrossRef
426.
Palomo C, Zou X, Nicholson IC, Bützler C, Brüggemann M. B-cell tumorigenesis in mice carrying a yeast artificial chromosome-based immunoglobulin heavy/c-myc translocus is independent of the heavy chain intron enhancer (Eμ). Cancer Res. 1999;59:5625–8.PubMed
427.
428.
429.
Sung SP, Joong SK, Tessarollo L, Owens JD, Peng L, Seong SH, et al. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice. Cancer Res. 2005;65:1306–15.CrossRef
430.
Janz S. Myc translocations in B cell and plasma cell neoplasms. DNA Repair (Amst). 2006;5:9–10.CrossRef
431.
Hemann MT, Bric A, Teruya-Feldstein J, Herbst A, Nilsson JA, Cordon-Cardo C, et al. Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants. Nature. 2005;436:807–11.PubMedPubMedCentralCrossRef
432.
Yu D, Thomas-Tikhonenko A. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis. Oncogene. 2002;21:1922–7.PubMedCrossRef
433.
Yu D, Allman D, Goldschmidt MH, Atchison ML, Monroe JG, Thomas-Tikhonenko A. Oscillation between B-lymphoid and myeloid lineages in Myc-induced hematopoietic tumors following spontaneous silencing/reactivation of the EBF/Pax5 pathway. Blood. 2003;101:1950–5.PubMedCrossRef
434.
Kawagoe H, Kandilci A, Kranenburg TA, Grosveld GC. Overexpression of N-Myc rapidly causes acute myeloid leukemia in mice. Cancer Res. 2007;67:10677–85.PubMedCrossRef
435.
436.
Sheikh-Zeineddini N, Bashash D, Safaroghli-Azar A, Riyahi N, Shabestari RM, Janzamin E, et al. Suppression of c-Myc using 10058–F4 exerts caspase-3-dependent apoptosis and intensifies the antileukemic effect of vincristine in pre-B acute lymphoblastic leukemia cells. J Cell Biochem. 2019;120:14004–16.PubMedCrossRef
437.
Allen A, Gill K, Hoehn D, Sulis M, Bhagat G, Alobeid B. C-myc protein expression in B-cell acute lymphoblastic leukemia, prognostic significance? Leuk Res. 2014;36:1061–6.CrossRef
438.
Moorman AV, Harrison CJ, Buck GAN, Richards SM, Secker-Walker LM, Martineau M, et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. Blood. 2007;109:3189–97.PubMedCrossRef
439.
Sawyers CL, Callahan W, Witte ON. Dominant negative MYC blocks transformation by ABL oncogenes. Cell. 1992;70:901–10.PubMedCrossRef
440.
Advani AS, Pendergast AM. Bcr-Abl variants: Biological and clinical aspects. Leuk Res. 2002;26:713–20.PubMedCrossRef
441.
Afar DEH, Goga A, McLaughlin J, Witte ON, Sawyers CL. Differential complementation of Bcr-Abl point mutants with c-Myc. Science (80- ). 1994;264:424–6.CrossRef
442.
Eswaran J, Sinclair P, Heidenreich O, Irving J, Russell LJ, Hall A, et al. The pre-B-cell receptor checkpoint in acute lymphoblastic leukaemia. Leukemia. 2015;29:1623–31.PubMedCrossRef
443.
Köhrer S, Havranek O, Seyfried F, Hurtz C, Coffey GP, Kim E, et al. Pre-BCR signaling in precursor B-cell acute lymphoblastic leukemia regulates PI3K/AKT, FOXO1 and MYC, and can be targeted by SYK inhibition. Leukemia. 2016;30:1246–54.PubMedPubMedCentralCrossRef
444.
Wallington-Beddoe CT, Powell JA, Tong D, Pitson SM, Bradstock KF, Bendall LJ. Sphingosine kinase 2 promotes acute lymphoblastic leukemia by enhancing myc expression. Cancer Res. 2014;74:2803–15.PubMedCrossRef
445.
Britten CD, Garrett-Mayer E, Chin SH, Shirai K, Ogretmen B, Bentz TA, et al. A phase I study of ABC294640, a first-in-class sphingosine kinase-2 inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 2017;23:4642–50.PubMedPubMedCentralCrossRef
446.
Wickline ED, Du Y, Stolz DB, Kahn M, Monga SPS. γ-Catenin at adherens junctions: mechanism and biologic implications in hepatocellular cancer after β-catenin knockdown. Neoplasia (United States). 2013;15:421.CrossRef
447.
Luong-Gardiol N, Siddiqui I, Pizzitola I, Jeevan-Raj B, Charmoy M, Huang Y, et al. γ-Catenin-dependent signals maintain BCR-ABL1 + B cell acute lymphoblastic leukemia. Cancer Cell. 2019;35:649–63.PubMedCrossRef
448.
O’hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12:513–26.PubMedCrossRef
449.
Krysov S, Dias S, Paterson A, Mockridge CI, Potter KN, Smith KA, et al. Surface IgM stimulation induces MEK1/2-dependent MYC expression in chronic lymphocytic leukemia cells. Blood. 2012;119:170–9.PubMedCrossRef
450.
Yeomans A, Thirdborough SM, Valle-Argos B, Linley A, Krysov S, Hidalgo MS, et al. Engagement of the B-cell receptor of chronic lymphocytic leukemia cells drives global and MYC-specific mRNA translation. Blood. 2016;127:449–57.PubMedCrossRef
451.
Pelletier J, Graff J, Ruggero D, Sonenberg N. Targeting the eIF4F translation initiation complex: a critical nexus for cancer development. Cancer Res. 2015;75:250–63.PubMedPubMedCentralCrossRef
452.
Lin CJ, Cencic R, Mills JR, Robert F, Pelletier J. c-Myc and eIF4F are components of a feedforward loop that links transcription and translation. Cancer Res. 2008;68:5326–34.PubMedCrossRef
453.
Sharma N, Magistroni V, Piazza R, Citterio S, Mezzatesta C, Khandelwal P, et al. BCR/ABL1 and BCR are under the transcriptional control of the MYC oncogene. Mol Cancer. 2015;14:1–11.CrossRef
454.
Xie S, Lin H, Sun T, Arlinghaus RB. Jak2 is involved in c-Myc induction by Bcr-Abl. Oncogene. 2002;21:7137–46.PubMedCrossRef
455.
Wu SC, Li LS, Kopp N, Montero J, Chapuy B, Yoda A, et al. Activity of the type II JAK2 inhibitor CHZ868 in B cell acute lymphoblastic leukemia. Cancer Cell. 2015;28(29):41.
456.
Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, et al. Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets. Blood. 2007;110:4055–63.PubMedCrossRef
457.
Shinohara H, Taniguchi K, Kumazaki M, Yamada N, Ito Y, Otsuki Y, et al. Anti-cancer fatty-acid derivative induces autophagic cell death through modulation of PKM isoform expression profile mediated by bcr-abl in chronic myeloid leukemia. Cancer Lett. 2015;360:28–38.PubMedCrossRef
458.
Shinohara H, Kumazaki M, Minami Y, Ito Y, Sugito N, Kuranaga Y, et al. Perturbation of energy metabolism by fatty-acid derivative AIC-47 and imatinib in BCR-ABL-harboring leukemic cells. Cancer Lett. 2016;371:1–11.PubMedCrossRef
459.
Shinohara H, Sugito N, Kuranaga Y, Heishima K, Minami Y, Naoe T, et al. Potent antiproliferative effect of fatty-acid derivative AIC-47 on leukemic mice harboring BCR-ABL mutation. Cancer Sci. 2019;110:751–60.PubMedPubMedCentralCrossRef
460.
Borkhardt A, Cazzaniga G, Viehmann S, Valsecchi MG, Ludwig WD, Burci L, et al. Incidence and clinical relevance of TEL/AML1 fusion genes in children with acute lymphoblastic leukemia enrolled in the German and Italian multicenter therapy trials. Blood. 1997;90:571–7.PubMedCrossRef
461.
Schäfer D, Olsen M, Lähnemann D, Stanulla M, Slany R, Schmiegelow K, et al. Five percent of healthy newborns have an ETV6-RUNX1 fusion as revealed by DNA-based GIPFEL screening. Blood. 2018;131:821–6.PubMedPubMedCentralCrossRef
462.
Cazzaniga G, Daniotti M, Tosi S, Giudici G, Aloisi A, Pogliani E, et al. The paired box domain gene PAX5 is fused to ETV6/TEL in an acute lymphoblastic leukemia case. Cancer Res. 2001;61:4666–70.PubMed
463.
Smeenk L, Fischer M, Jurado S, Jaritz M, Azaryan A, Werner B, et al. Molecular role of the PAX 5- ETV 6 oncoprotein in promoting B-cell acute lymphoblastic leukemia. EMBO J. 2017;36:718–35.PubMedPubMedCentralCrossRef
464.
465.
466.
Mangolini M, De Boer J, Walf-Vorderwülbecke V, Pieters R, Den Boer ML, Williams O. STAT3 mediates oncogenic addiction to TEL-AML1 in t(12;21) acute lymphoblastic leukemia. Blood. 2013;122:542–9.PubMedCrossRef
467.
Stoskus M, Vaitkeviciene G, Eidukaite A, Griskevicius L. ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia. Blood Cells Mol Dis. 2016;57:30–4.PubMedCrossRef
468.
Stöhr N, Hüttelmaier S. IGF2BP1: a post-transcriptional “driver” of tumor cell migration. Cell Adhes Migr. 2012;6:312–8.CrossRef
469.
Montaño A, Ordoñez JL, Alonso-Pérez V, Hernández-Sánchez J, Santos S, González T, et al. ETV6/RUNX1 fusion gene abrogation decreases the oncogenicity of tumour cells in a preclinical model of acute lymphoblastic leukaemia. Cells. 2020;9:215.PubMedCentralCrossRef
470.
Sanjuan-Pla A, Bueno C, Prieto C, Acha P, Stam RW, Marschalek R, et al. Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia. Blood. 2015;126:2676–85.PubMedPubMedCentralCrossRef
471.
Meeker ND, Cherry AM, Bangs CD, Frazer JK. A pediatric B lineage leukemia with coincident MYC and MLL translocations. J Pediatr Hematol Oncol. 2011;33:158–60.PubMedCrossRef
472.
Chowdhury T, Brady HJM. Insights from clinical studies into the role of the MLL gene in infant and childhood leukemia. Blood Cells Mol Dis. 2008;40:192–9.PubMedCrossRef
473.
Xu N, Li YL, Zhou X, Cao R, Li H, Lu QS, et al. CDKN2 gene deletion as poor prognosis predictor involved in the progression of adult B-lineage acute lymphoblastic leukemia patients. J Cancer. 2015;6:1114.PubMedPubMedCentralCrossRef
474.
Ragusa D, Makarov EM, Britten O, Moralli D, Green CM, Tosi S. The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): revised characterisation of cytogenetic features. Cancer Rep. 2019;2:e1207.
475.
Hyrenius-Wittsten A, Pilheden M, Sturesson H, Hansson J, Walsh MP, Song G, et al. De novo activating mutations drive clonal evolution and enhance clonal fitness in KMT2A-rearranged leukemia. Nat Commun. 2018;9:1–13.CrossRef
476.
Neff T, Sinha AU, Kluk MJ, Zhu N, Khattab MH, Stein L, et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc Natl Acad Sci U S A. 2012;109:5028–33.PubMedPubMedCentralCrossRef
477.
Meyer C, Burmeister T, Gröger D, Tsaur G, Fechina L, Renneville A, et al. The MLL recombinome of acute leukemias in 2017. Leukemia. 2018;32:273–84.PubMedCrossRef
478.
Schreiner S, Birke M, García-Cuéllar MP, Zilles O, Greil J, Slany RK. MLL-ENL causes a reversible and myc-dependent block of myelomonocytic cell differentiation. Cancer Res. 2001;61:6480–6.PubMed
479.
Jiang X, Huang H, Li Z, Li Y, Wang X, Gurbuxani S, et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012;22:524–35.PubMedPubMedCentralCrossRef
480.
Sacco JJ, Coulson JM, Clague MJ, Urbé S. Emerging roles of deubiquitinases in cancer-associated pathways. IUBMB Life. 2010;62:140–57.PubMedPubMedCentral
481.
Meyer C, Lopes BA, Caye-Eude A, Cavé H, Arfeuille C, Cuccuini W, et al. Human MLL/KMT2A gene exhibits a second breakpoint cluster region for recurrent MLL–USP2 fusions. Leukemia. 2019;33:2306–40.PubMedPubMedCentralCrossRef
482.
Delmore JE, Issa GC, Lemieux ME, Rahl PB, Shi J, Jacobs HM, et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell. 2011;146:904–17.PubMedPubMedCentralCrossRef
483.
Dawson MA, Prinjha RK, Dittmann A, Giotopoulos G, Bantscheff M, Chan WI, et al. Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia. Nature. 2011;478:529–33.PubMedPubMedCentralCrossRef
484.
Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–52.PubMedPubMedCentralCrossRef
485.
Luo Z, Lin C, Guest E, Garrett AS, Mohaghegh N, Swanson S, et al. The super elongation complex family of RNA polymerase II elongation factors: gene target specificity and transcriptional output. Mol Cell Biol. 2012;32:2608–17.PubMedPubMedCentralCrossRef
486.
Luo Z, Lin C, Shilatifard A. The super elongation complex (SEC) family in transcriptional control. Nat Rev Mol Cell Biol. 2012;13:543–7.PubMedCrossRef
487.
488.
Bisgrove DA, Mahmoudi T, Henklein P, Verdin E. Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription. Proc Natl Acad Sci U S A. 2007;104:13690–5.PubMedPubMedCentralCrossRef
489.
Bowry A, Piberger AL, Rojas P, Saponaro M, Petermann E. BET inhibition induces HEXIM1- and RAD51-dependent conflicts between transcription and replication. Cell Rep. 2018;25:2061–9.PubMedPubMedCentralCrossRef
490.
Dey A, Chao SH, Lane DP. HEXIM1 and the control of transcription elongation: from cancer and inflammation to AIDS and cardiac hypertrophy. Cell Cycle. 2007;6:1856–63.PubMedCrossRef
491.
Roulin L, Ali A, Masse A, Coudé M-M, Bluteau D, Braun T, et al. Activity of OTX015 (MK-8628), a BET-bromodomain inhibitor, in acute myeloid leukemia (AML) progenitor cells. Blood. 2015;126:2588.CrossRef
492.
Astorgues-Xerri L, Vázquez R, Odore E, Rezai K, Kahatt C, Mackenzie S, et al. Insights into the cellular pharmacological properties of the BET-inhibitor OTX015/MK-8628 (birabresib), alone and in combination, in leukemia models. Leuk Lymphoma. 2019;60:3067–70.PubMedCrossRef
493.
Coudé MM, Braun T, Berrou J, Dupont M, Bertrand S, Masse A, et al. BET inhibitor OTX015 targets BRD2 and BRD4 and decreases c-MYC in acute leukemia cells. Oncotarget. 2015;6:17698.PubMedPubMedCentralCrossRef
494.
Berthon C, Raffoux E, Thomas X, Vey N, Gomez-Roca C, Yee K, et al. Bromodomain inhibitor OTX015 in patients with acute leukaemia: A dose-escalation, phase 1 study. Lancet Haematol. 2016;3:e186–95.PubMedCrossRef
495.
Odore E, Lokiec F, Cvitkovic E, Bekradda M, Herait P, Bourdel F, et al. Phase I population pharmacokinetic assessment of the oral bromodomain inhibitor OTX015 in patients with haematologic malignancies. Clin Pharmacokinet. 2016;55:397–405.PubMedCrossRef
496.
Alqahtani A, Choucair K, Ashraf M, Hammouda DM, Alloghbi A, Khan T, et al. Bromodomain and extra-terminal motif inhibitors: a review of preclinical and clinical advances in cancer therapy. Future Sci OA. 2019;5:FSO372.PubMedPubMedCentralCrossRef
497.
Siu KT, Ramachandran J, Yee AJ, Eda H, Santo L, Panaroni C, et al. Preclinical activity of CPI-0610, a novel small-molecule bromodomain and extra-terminal protein inhibitor in the therapy of multiple myeloma. Leukemia. 2017;31:1760–9.PubMedCrossRef
498.
Kremyanskaya M, Hoffman R, Mascarenhas J, Verstovsek S, Mertz J, Garner F, et al. A Phase 2 study of Cpi-0610, a bromodomain and extraterminal (BET) inhibitor, in patients with myelofibrosis (MF). Blood. 2018;132:5481.CrossRef
499.
Vega-García N, Malatesta R, Estella C, Pérez-Jaume S, Esperanza-Cebollada E, Torrebadell M, et al. Paediatric patients with acute leukaemia and KMT2A (MLL) rearrangement show a distinctive expression pattern of histone deacetylases. Br J Haematol. 2018;182:542–53.PubMedCrossRef
500.
José-Enériz ES, Gimenez-Camino N, Agirre X, Prosper F. HDAC inhibitors in acute myeloid leukemia. Cancers (Basel). 2019;11:1794.CrossRef
501.
Mummery A, Narendran A, Lee K-Y. Targeting epigenetics through histone deacetylase inhibitors in acute lymphoblastic leukemia. Curr Cancer Drug Targets. 2011;11:882–93.PubMedPubMedCentralCrossRef
502.
Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, et al. SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells. Cell Stem Cell. 2014;15:431–46.PubMedPubMedCentralCrossRef
503.
Zehtabcheh S, Yousefi AM, Salari S, Safa M, Momeny M, Ghaffari SH, et al. Abrogation of histone deacetylases (HDACs) decreases survival of chronic myeloid leukemia cells: new insight into attenuating effects of the PI3K/c-Myc axis on panobinostat cytotoxicity. Cell Biol Int. 2021;45:1111–21.PubMedCrossRef
504.
Suraweera A, O’Byrne KJ, Richard DJ. Combination therapy with histone deacetylase inhibitors (HDACi) for the treatment of cancer: Achieving the full therapeutic potential of HDACi. Front Oncol. 2018;8:92.PubMedPubMedCentralCrossRef
505.
Barneda-Zahonero B, Collazo O, Azagra A, Fernández-Duran I, Serra-Musach J, Islam ABMMK, et al. The transcriptional repressor HDAC7 promotes apoptosis and c-Myc downregulation in particular types of leukemia and lymphoma. Cell Death Dis. 2015;6:e1635.PubMedPubMedCentralCrossRef
506.
Haery L, Thompson RC, Gilmore TD. Histone acetyltransferases and histone deacetylases in B- and T-cell development, physiology and malignancy. Genes Cancer. 2015;6:184.PubMedPubMedCentralCrossRef
507.
Verza FA, Das U, Fachin AL, Dimmock JR, Marins M. Roles of histone deacetylases and inhibitors in anticancer therapy. Cancers (Basel). 2020;12:1664.CrossRef
508.
Shi J, Whyte WA, Zepeda-Mendoza CJ, Milazzo JP, Shen C, Roe JS, et al. Role of SWI/SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 2013;27:2648–62.PubMedPubMedCentralCrossRef
509.
Benetatos L, Benetatou A, Vartholomatos G. Enhancers and MYC interplay in hematopoiesis. J Mol Med. 2020;98:471–81.PubMedCrossRef
510.
Bahr C, von Palekse L, Uslu V, Remeseiro S, Takayama N, Ng S, et al. A cluster of enhancer modules directs differential MYC expression along the normal and leukemic haematopoietic stem cell hierarchies. Blood. 2017;130:1150.
511.
Horton SJ, Jaques J, Woolthuis C, Van Dijk J, Mesuraca M, Huls G, et al. MLL-AF9-mediated immortalization of human hematopoietic cells along different lineages changes during ontogeny. Leukemia. 2013;27:1116–26.PubMedCrossRef
512.
Bahr C, Von Paleske L, Uslu VV, Remeseiro S, Takayama N, Ng SW, et al. A Myc enhancer cluster regulates normal and leukaemic haematopoietic stem cell hierarchies. Nature. 2018;553:515–20.PubMedCrossRef
513.
Speedy HE, Beekman R, Chapaprieta V, Orlando G, Law PJ, Martín-García D, et al. Insight into genetic predisposition to chronic lymphocytic leukemia from integrative epigenomics. Nat Commun. 2019;10:1–9.CrossRef
514.
Shuai W, Lin P, Strati P, Patel KP, Routbort MJ, Hu S, et al. Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020;10:1–11.CrossRef
515.
Huh YO, Lin KIC, Vega F, Schlette E, Yin CC, Keating MJ, et al. MYC translocation in chronic lymphocytic leukaemia is associated with increased prolymphocytes and a poor prognosis. Br J Haematol. 2008;142:36–44.PubMedCrossRef
516.
Kuriakose P, Perveen N, Maeda K, Wiktor A, Van Dyke DL. Translocation (8;14)(q24;q32) as the sole cytogenetic abnormality in B-cell prolymphocytic leukemia. Cancer Genet Cytogenet. 2004;150:156–8.PubMedCrossRef
517.
Dai HP, Xue YQ, Zhang J, Wu YF, Pan JL, Wang Y, et al. Translocation t(2;8)(p12;q24) in two patients with B cell chronic lymphocytic leukemia. Acta Haematol. 2009;120:232–6.CrossRef
518.
Li Y, Hu S, Wang SA, Li S, Huh YO, Tang Z, et al. The clinical significance of 8q24/MYC rearrangement in chronic lymphocytic leukemia. Mod Pathol. 2016;29:444–51.PubMedCrossRef
519.
520.
Filip D, Mraz M. The role of MYC in the transformation and aggressiveness of ‘indolent’ B-cell malignancies. Leuk Lymphoma. 2020;61:510–24.PubMedCrossRef
521.
Mihailovich M, Bremang M, Spadotto V, Musiani D, Vitale E, Varano G, et al. MiR-17-92 fine-tunes MYC expression and function to ensure optimal B cell lymphoma growth. Nat Commun. 2015;6:1–15.CrossRef
522.
De Paoli L, Cerri M, Monti S, Rasi S, Spina V, Bruscaggin A, et al. MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia. Leuk Lymphoma. 2013;54:1087–90.PubMedCrossRef
523.
Fabbri G, Holmes AB, Viganotti M, Scuoppo C, Belver L, Herranz D, et al. Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2017;114:E2911–9.PubMedPubMedCentralCrossRef
524.
Zhang W, Kater AP, Widhopf GF, Chuang HY, Enzler T, James DF, et al. B-cell activating factor and v-Myc myelocytomatosis viral oncogene homolog (c-Myc) influence progression of chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2010;107:18956–60.PubMedPubMedCentralCrossRef
525.
Wang WG, Liu ZB, Jiang XN, Lee J, Zhou XY, Li XQ. MYC protein dysregulation is driven by BCR-PI3K signalling in diffuse large B-cell lymphoma. Histopathology. 2017;71:778–85.PubMedCrossRef
526.
Seda V, Mraz M. B-cell receptor signalling and its crosstalk with other pathways in normal and malignant cells. Eur J Haematol. 2015;94:193–205.PubMedCrossRef
527.
Coelho V, Krysov S, Ghaemmaghami AM, Emara M, Potter KN, Johnson P, et al. Glycosylation of surface Ig creates a functional bridge between human follicular lymphoma and microenvironmental lectins. Proc Natl Acad Sci U S A. 2010;107:18587–15892.PubMedPubMedCentralCrossRef
528.
Radcliffe CM, Arnold JN, Suter DM, Wormald MR, Harvey DJ, Royle L, et al. Human follicular lymphoma cells contain oligomannose glycans in the antigen-binding site of the B-cell receptor. J Biol Chem. 2007;282:7405–15.PubMedCrossRef
529.
Krysov S, Potter KN, Mockridge CI, Coelho V, Wheatley I, Packham G, et al. Surface IgM of CLL cells displays unusual glycans indicative of engagement of antigen in vivo. Blood. 2010;115:4198–205.PubMedCrossRef
530.
Ntoufa S, Papakonstantinou N, Apollonio B, Gounari M, Galigalidou C, Fonte E, et al. B cell anergy modulated by TLR1/2 and the miR-17∼92 cluster underlies the indolent clinical course of chronic lymphocytic leukemia stereotyped subset #4. J Immunol. 2016;196:4410–7.PubMedCrossRef
531.
532.
Psathas JN, Doonan PJ, Raman P, Freedman BD, Minn AJ, Thomas-Tikhonenko A. Lymphoid neoplasia: the Myc-miR-17-92 axis amplifies B-cell receptor signaling via inhibition of ITIM proteins—a novel lymphomagenic feed-forward loop. Blood. 2013;122:4220–9.PubMedPubMedCentralCrossRef
533.
Mraz M, Chen L, Rassenti LZ, Ghia EM, Li H, Jepsen K, et al. MiR-150 influences B-cell receptor signaling in chronic lymphocytic leukemia by regulating expression of GAB1 and FOXP1. Blood. 2014;124:84–95.PubMedPubMedCentralCrossRef
534.
Cerna K, Oppelt J, Chochola V, Musilova K, Seda V, Pavlasova G, et al. MicroRNA miR-34a downregulates FOXP1 during DNA damage response to limit BCR signalling in chronic lymphocytic leukaemia B cells. Leukemia. 2019;33:403–14.PubMedCrossRef
535.
Mraz M, Malinova K, Kotaskova J, Pavlova S, Tichy B, Malcikova J, et al. miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities. Leukemia. 2009;23:1159–63.PubMedCrossRef
536.
Rozovski U, Keating MJ, Estrov Z. Why Is the immunoglobulin heavy chain gene mutation status a prognostic indicator in chronic lymphocytic leukemia? Acta Haematol. 2018;140:51–4.PubMedCrossRef
537.
Rotbain EC, Frederiksen H, Hjalgrim H, Rostgaard K, Egholm GJ, Zahedi B, et al. IGHV mutational status and outcome for patients with chronic lymphocytic leukemia upon treatment: a danish nationwide population-based study. Haematologica. 2020;105:1621.PubMedPubMedCentralCrossRef
538.
D’Avola A, Drennan S, Tracy I, Henderson I, Chiecchio L, Larrayoz M, et al. Surface IgM expression and function are associated with clinical behavior, genetic abnormalities, and DNA methylation in CLL. Blood. 2016;128:816–26.PubMedCrossRef
539.
Arruga F, Bracciamà V, Yeomans A, D’Avola A, Coscia M, D’Arena GF, et al. NOTCH1 stabilization By PEST mutations enhances IgM-mediated activity in chronic lymphocytic leukemia. Blood. 2018;132:1832.CrossRef
540.
D’Avola A, Yeomans A, Drennan S, Rose-Zerilli M, Strefford JC, Stevenson FK, et al. Global and MYC-specific translation is enhanced in activated chronic lymphocytic leukemia cells carrying NOTCH1 C7541_7542delct mutations. Blood. 2016;128:970.CrossRef
541.
DelPapa B, Baldoni S, Dorillo E, DeFalco F, Rompietti C, Cecchini D, et al. Decreased NOTch1 activation correlates with response to ibrutinib in chronic lymphocytic leukemia. Clin Cancer Res. 2019;25:7540–53.CrossRef
542.
543.
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, et al. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: a real world experience. Blood. 2016;128:2199–205.PubMedCrossRef
544.
Kim E, ten Hacken E, Sivina M, Clarke A, Thompson PA, Jain N, et al. The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia. 2020;34:1588–98.PubMedCrossRef
545.
Carrà G, Panuzzo C, Morena D, Lingua MF, Fantino C, Brancaccio M, et al. BET inhibitors in chronic lymphocytic leukemia: JQ1 synergizes with venetoclax in promoting apoptosis. Blood. 2017;130:2542.
546.
Burger JA, O’Brien S. Evolution of CLL treatment—from chemoimmunotherapy to targeted and individualized therapy. Nat Rev Clin Oncol. 2018;15:510–27.PubMedCrossRef
547.
Dalla-Favera R, Bregni M, Erikson J, Patterson D, Gallo RC, Croce CM. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells. Proc Natl Acad Sci U S A. 1982;79:7824–7.PubMedPubMedCentralCrossRef
548.
Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. Genes (Basel). 2017;8:116.CrossRef
549.
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.PubMedCrossRef
550.
Seegmiller AC, Garcia R, Huang R, Maleki A, Karandikar NJ, Chen W. Simple karyotype and bcl-6 expression predict a diagnosis of Burkitt lymphoma and better survival in IG-MYC rearranged high-grade B-cell lymphomas. Mod Pathol. 2010;23:909–20.PubMedCrossRef
551.
Einerson RR, Law ME, Blair HE, Kurtin PJ, McClure RF, Ketterling RP, et al. Novel FISH probes designed to detect IGK-MYC and IGL-MYC rearrangements in B-cell lineage malignancy identify a new breakpoint cluster region designated BVR2. Leukemia. 2006;20:1790–9.PubMedCrossRef
552.
Bemark M, Neuberger MS. The c-MYC allele that is translocated into the IgH locus undergoes constitutive hypermutation in a Burkitt’s lymphoma line. Oncogene. 2000;19:3404–10.PubMedCrossRef
553.
Cesarman E, Dalla-Favera R, Bentley D, Groudine M. Mutations in the first exon are associated with altered transcription of c-myc in Burkitt lymphoma. Science (80- ). 1987;238:1272–5.CrossRef
554.
Rabbitts TH, Forster A, Hamlyn P, Baer R. Effect of somatic mutation within translocated c-myc genes in Burkitt’s lymphoma. Nature. 1984;309:592–7.PubMedCrossRef
555.
Schmitz R, Young RM, Ceribelli M, Jhavar S, Xiao W, Zhang M, et al. Burkitt lymphoma pathogenesis and therapeutic targets from structural and functional genomics. Nature. 2012;490:116–20.PubMedPubMedCentralCrossRef
556.
557.
Pan L, Sato S, Frederick JP, Sun X-H, Zhuang Y. Impaired immune responses and B-cell proliferation in mice lacking the Id3 gene. Mol Cell Biol. 1999;19:5969–80.PubMedPubMedCentralCrossRef
558.
Schiffman JD, Lorimer PD, Rodic V, Jahromi MS, Downie JM, Bayerl MG, et al. Genome wide copy number analysis of paediatric Burkitt lymphoma using formalin-fixed tissues reveals a subset with gain of chromosome 13q and corresponding miRNA over expression. Br J Haematol. 2011;155:477–86.PubMedPubMedCentralCrossRef
559.
Srinivasan L, Sasaki Y, Calado DP, Zhang B, Paik JH, DePinho RA, et al. PI3 kinase signals BCR-dependent mature B cell survival. Cell. 2009;139:573–86.PubMedPubMedCentralCrossRef
560.
Dinneen K, Timlin DM, O’Hare K, Walker J, Castriciano G, Connolly Y, et al. Incidence of single hit Bcl-2 and Bcl-6 rearrangements in DLBCL: the Irish experience. J Clin Pathol. 2020;73:689–90.PubMedCrossRef
561.
Valera A, López-Guillermo A, Cardesa-Salzmann T, Climent F, González-Barca E, Mercadal S, et al. MYC protein expression and genetic alterations have prognostic impact in patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Haematologica. 2013;98:1554.PubMedPubMedCentralCrossRef
562.
563.
Pfeifer M, Grau M, Lenze D, Wenzel SS, Wolf A, Wollert-Wulf B, et al. PTEN loss defines a PI3K/AKT pathway-dependent germinal center subtype of diffuse large B-cell lymphoma. Proc Natl Acad Sci U S A. 2013;110:12420–5.PubMedPubMedCentralCrossRef
564.
Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci. 2007;98:1482–90.PubMedCrossRef
565.
566.
Ziemba JB, Wolf Z, Weinstock M, Asakrah S. Double-hit and triple-hit follicular lymphoma. Am J Clin Pathol. 2020;153:672–85.PubMedCrossRef
567.
Grimm KE, O’Malley DP. Aggressive B cell lymphomas in the 2017 revised WHO classification of tumors of hematopoietic and lymphoid tissues. Ann Diagn Pathol. 2019;38:6–10.PubMedCrossRef
568.
Gebauer N, Bernard V, Gebauer W, Thorns C, Feller AC, Merz H. TP53 mutations are frequent events in double-hit B-cell lymphomas with MYC and BCL2 but not MYC and BCL6 translocations. Leuk Lymphoma. 2015;56:179–85.PubMedCrossRef
569.
Li W, Gupta SK, Han W, Kundson RA, Nelson S, Knutson D, et al. Targeting MYC activity in double-hit lymphoma with MYC and BCL2 and/or BCL6 rearrangements with epigenetic bromodomain inhibitors. J Hematol Oncol. 2019;12:1–13.CrossRef
570.
Freedman A, Jacobsen E. Follicular lymphoma: 2020 update on diagnosis and management. Am J Hematol. 2020;95:316–27.PubMedCrossRef
571.
Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, et al. Population-based analysis of incidence and outcome of transformed non-hodgkin’s lymphoma. J Clin Oncol. 2008;26:5165–9.PubMedCrossRef
572.
Aukema SM, van Pel R, Nagel I, Bens S, Siebert R, Rosati S, et al. MYC expression and translocation analyses in low-grade and transformed follicular lymphoma. Histopathology. 2017;71:960–71.PubMedCrossRef
573.
Chisholm KM, Bangs CD, Bacchi CE, Molina-Kirsch H, Cherry A, Natkunam Y. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39:294–303.PubMedCrossRef
574.
575.
Hanel W, Epperla N. Emerging therapies in mantle cell lymphoma. J Hematol Oncol. 2020;13:1–18.CrossRef
576.
Yatabe Y, Suzuki R, Tobinai K, Matsuno Y, Ichinohasama R, Okamoto M, et al. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: a clinicopathologic comparison of cyclin D1-positive MCL and cyclin D1-negative MCL-like B-cell lymphoma. Blood. 2000;95:2253–61.PubMed
577.
Wang M, Sun L, Qian J, Han X, Zhang L, Lin P, et al. Cyclin D1 as a universally expressed mantle cell lymphoma-associated tumor antigen for immunotherapy. Leukemia. 2009;23:1320–8.PubMedPubMedCentralCrossRef
578.
Zhou J, Hu L, Zuo M, Zhou Y, Li G, Zhang X. An uncommon case of double-hit mantle cell lymphoma that demonstrates a transformation process. Am J Clin Pathol. 2020;153:49–57.PubMedCrossRef
579.
Setoodeh R, Schwartz S, Papenhausen P, Zhang L, Sagatys EM, Moscinski LC, et al. Double-hit mantle cell lymphoma with MYC gene rearrangement or amplification: a report of four cases and review of the literature. Int J Clin Exp Pathol. 2013;6:155.PubMedPubMedCentral
580.
Kolodziej M, Jesionek-Kupnicka D, Braun M, Atamanyuk V, Sloniec S, Cebulski J, et al. Classification of aggressive and classic mantle cell lymphomas using synchrotron Fourier Transform Infrared microspectroscopy. Sci Rep. 2019;9:1–8.CrossRef
581.
Royo C, Salaverria I, Hartmann EM, Rosenwald A, Campo E, Beà S. The complex landscape of genetic alterations in mantle cell lymphoma. In: Seminars in cancer biology. 2011.
582.
Hao S, Sanger W, Onciu M, Lai R, Schlette EJ, Medeiros LJ. Mantle cell lymphoma with 8q24 chromosomal abnormalities: a report of 5 cases with blastoid features. Mod Pathol. 2002;15:1266–72.PubMedCrossRef
583.
Hu Z, Medeiros LJ, Chen Z, Chen W, Li S, Konoplev SN, et al. Mantle cell lymphoma with MYC rearrangement: a report of 17 patients. Am J Surg Pathol. 2017;41:216–24.PubMedCrossRef
584.
Sander B, Quintanilla-Martinez L, Ott G, Xerri L, Kuzu I, Chan JKC, et al. Mantle cell lymphoma—a spectrum from indolent to aggressive disease. Virchows Arch. 2016;468:245–57.PubMedCrossRef
585.
Swerdlow SH, Campo E, Pileri SA, Lee Harris N, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–90.PubMedPubMedCentralCrossRef
586.
Castillo JJ, Bibas M, Miranda RN. The biology and treatment of plasmablastic lymphoma. Blood. 2015;125:2323–30.PubMedCrossRef
587.
Li YJ, Li JW, Chen KL, Li J, Zhong MZ, Liu XL, et al. HIV-negative plasmablastic lymphoma: report of 8 cases and a comprehensive review of 394 published cases. Blood Res. 2020;55:49.PubMedPubMedCentralCrossRef
588.
Yamada T, Kitamura N, Sasabe E, Yamamoto T. Plasmablastic lymphoma of the upper gingiva in an HIV-negative elderly patient. Oral Maxillofac Surg Cases. 2015;1:19–24.CrossRef
589.
Shaffer AL, Lin KI, Kuo TC, Yu X, Hurt EM, Rosenwald A, et al. Blimp-1 orchestrates plasma cell differentiation by extinguishing the mature B cell gene expression program. Immunity. 2002;17:51–62.PubMedCrossRef
590.
Sciammas R, Davis MM. Modular nature of blimp-1 in the regulation of gene expression during b cell maturation. J Immunol. 2004;172:5427–40.PubMedCrossRef
591.
Montes-Moreno S, Martinez-Magunacelaya N, Zecchini-Barrese T, De Villambrosía SG, Linares E, Ranchal T, et al. Plasmablastic lymphoma phenotype is determined by genetic alterations in MYC and PRDM1. Mod Pathol. 2017;30:85–94.PubMedCrossRef
592.
Valera A, Balagué O, Colomo L, Martínez A, Delabie J, Taddesse-Heath L, et al. IG/MYC rearrangements are the main cytogenetic alteration in plasmablastic lymphomas. Am J Surg Pathol. 2010;34:1686.PubMedPubMedCentralCrossRef
593.
Taddesse-Heath L, Meloni-Ehrig A, Scheerle J, Kelly JC, Jaffe ES. Plasmablastic lymphoma with MYC translocation: evidence for a common pathway in the generation of plasmablastic features. Mod Pathol. 2010;23:991–9.PubMedPubMedCentralCrossRef
594.
Simonitsch-Klupp I, Hauser I, Ott G, Drach J, Ackermann J, Kaufmann J, et al. Diffuse large B-cell lymphomas with plasmablastic/plasmacytoid features are associated with TP53 deletions and poor clinical outcome. Leukemia. 2004;18:146–55.PubMedCrossRef
595.
Misund K, Keane N, Stein CK, Asmann YW, Day G, Welsh S, et al. MYC dysregulation in the progression of multiple myeloma. Leukemia. 2020;34:322–6.PubMedCrossRef
596.
Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2:175–87.CrossRefPubMed
597.
Abdallah N, Baughn LB, Vincent Rajkumar S, Kapoor P, Gertz MA, Dispenzieri A, et al. Implications of MYC rearrangements in newly diagnosed multiple myeloma. Clin Cancer Res. 2020;26:6581–8.PubMedPubMedCentralCrossRef
598.
Jovanović KK, Roche-Lestienne C, Ghobrial IM, Facon T, Quesnel B, Manier S. Targeting MYC in multiple myeloma. Leukemia. 2018;32:1295–306.PubMedCrossRef
599.
Manier S, Huynh D, Shen YJ, Zhou J, Yusufzai T, Salem KZ, et al. Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma. Sci Transl Med. 2017;9:eaal2668.PubMedPubMedCentralCrossRef
600.
Leon J, Ferrandiz N, Acosta JC, Delgado MD. Inhibition of cell differentiation: a critical mechanism for MYC-mediated carcinogenesis? Cell Cycle. 2009;8:1148–57.PubMedCrossRef
601.
Dmitrovsky E, Kuehl WM, Hollis GF, Kirsch IR, Bender TP, Segal S. Expression of a transfected human c-myconcogene inhibits differentiation of a mouse erythroleukaemia cell line. Nature. 1986;322:748–50.PubMedCrossRef
602.
Delgado MD, Lerga A, Cañelles M, Gómez-Casares MT, León J. Differential regulation of Max and role of c-Myc during erythroid and myelomonocytic differentiation of K562 cells. Oncogene. 1995;10:1659–66.PubMed
603.
Bahram F, Wu S, Öberg F, Lüscher B, Larsson L-G. Regulation posttranslational of Myc function in response to phorbol ester/interferon-γ–induced differentiation of v-Myc–transformed U-937 monoblasts. Blood. 1999;93:3900–12.PubMedCrossRef
604.
Uribesalgo I, Buschbeck M, Gutiérrez A, Teichmann S, Demajo S, Kuebler B, et al. E-box-independent regulation of transcription and differentiation by MYC. Nat Cell Biol. 2011;13:1443–9.PubMedCrossRef
605.
Albajar M, Gómez-Casares MT, Llorca J, Mauleon I, Vaqué JP, Acosta JC, et al. MYC in chronic myeloid leukemia: Induction of aberrant DNA synthesis and association with poor response to imatinib. Mol Cancer Res. 2011;9:564–76.PubMedCrossRef
606.
Skoda RC, Tsai SF, Orkin SH, Leder P. Expression of c-MYC under the control of GATA-1 regulatory sequences causes erythroleukemia in transgenic mice. J Exp Med. 1995;181:1603–13.PubMedCrossRef
607.
Luo H, Li Q, O’Neal J, Kreisel F, Le Beau MM, Tomasson MH. c-Myc rapidly induces acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations. Blood. 2005;106:2452–61.PubMedCrossRef
608.
Farhadi E, Safa M, Sharifi AM, Bashash D. PRIMA-1 induces caspase-mediated apoptosis in acute promyelocytic leukemia NB4 cells by inhibition of nuclear factor-κB and downregulation of Bcl-2, XIAP, and c-Myc. Anticancer Drugs. 2017;28:51–8.PubMedCrossRef
609.
Tang G, Hu S, Wang SA, Xie W, Lin P, Xu J, et al. t(3;8)(q26.2;q24) often leads to MECOM/MYC rearrangement and is commonly associated with therapy-related myeloid neoplasms and/or disease progression. J Mol Diagn. 2019;21:343–51.PubMedCrossRef
610.
Smith SC, Qdaisat TZS, Althof PA, Dave BJ, Sanmann JN. MECOM rearrangement involving the MYC locus: two additional patients with the rare translocation, t(3;8)(q26.2;q24), and molecular review. Leuk Res. 2020;95:106387.PubMedCrossRef
611.
Papaemmanuil E, Gerstung M, Bullinger L, Gaidzik VI, Paschka P, Roberts ND, et al. Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med. 2016;374:2209–21.PubMedPubMedCentralCrossRef
612.
Nanbakhsh A, Pochon C, Mallavialle A, Amsellem S, Bourhis JH, Chouaib S. C-Myc regulates expression of NKG2D ligands ULBP1/2/3 in AML and modulates their susceptibility to NK-mediated lysis. Blood. 2014;123:3585–95.PubMedPubMedCentralCrossRef
613.
614.
Brondfield S, Umesh S, Corella A, Zuber J, Rappaport AR, Gaillard C, et al. Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemother Pharmacol. 2015;76:35–46.PubMedPubMedCentralCrossRef
615.
Dickinson M, Kamdar M, Huntly BJ, Fernández De Larrea C, Cordoba R, Mateos M-V, et al. A phase i study of molibresib (GSK525762), a selective bromodomain (BRD) and extra terminal protein (BET) inhibitor: results from part 1 of a phase I/II open label single agent study in subjects with non-Hodgkin’s lymphoma (NHL). Blood. 2018;132:1682.CrossRef
616.
Wang Z, Guan W, Wang M, Chen J, Zhang L, Xiao Y, et al. AML1-ETO inhibits acute myeloid leukemia immune escape by CD48. Leuk Lymphoma. 2021;62:937–43.PubMedCrossRef
617.
Biernacki MA, Foster KA, Woodward KB, Coon ME, Cummings C, Cunningham TM, et al. CBFB-MYH11 fusion neoantigen enables T cell recognition and killing of acute myeloid leukemia. J Clin Invest. 2020;130:5127–41.PubMedPubMedCentralCrossRef
618.
Liquori A, Ibañez M, Sargas C, Sanz MÁ, Barragán E, Cervera J. Acute promyelocytic leukemia: a constellation of molecular events around a single PML-RARA fusion gene. Cancers (Basel). 2020;12:624.CrossRef
619.
620.
Yamaoka A, Suzuki M, Katayama S, Orihara D, Engel JD, Yamamoto M. EVI1 and GATA2 misexpression induced by inv(3)(q21q26) contribute to megakaryocyte-lineage skewing and leukemogenesis. Blood Adv. 2020;4:1722–36.PubMedPubMedCentralCrossRef
621.
622.
Kulemina O, Siordia N, Bogdanov K, Alexeeva J, Girshova L, Lomaia E, et al. BCR-ABL1+ AML de novo and CBF-Leukemia At Relapse: Game Of Clones. Blood. 2019;134:5138.CrossRef
623.
Numata A, Kwok HS, Kawasaki A, Li J, Zhou QL, Kerry J, et al. The basic helix-loop-helix transcription factor SHARP1 is an oncogenic driver in MLL-AF6 acute myelogenous leukemia. Nat Commun. 2018;9:1–16.CrossRef
624.
Anstee NS, Bilardi RA, Ng AP, Xu Z, Robati M, Vandenberg CJ, et al. Impact of elevated anti-apoptotic MCL-1 and BCL-2 on the development and treatment of MLL-AF9 AML in mice. Cell Death Differ. 2019;26:1316–31.PubMedCrossRef
625.
Kingsley MC, Riedel SS, Xie HM, Stabler SP, Pastuer T, Bernt KM. Tight regulation of H3K79 methylation levels in KMT2A-rearranged AML. Blood. 2018;132:3884.CrossRef
626.
Mohanty S, Jyotsana N, Sharma A, Kloos A, Gabdoulline R, Othman B, et al. Targeted inhibition of the nup98-nsd1 fusion oncogene in acute myeloid leukemia. Cancers (Basel). 2020;12:2766.CrossRef
627.
Di Nardo CD, Cortes JE. Mutations in AML: prognostic and therapeutic implications. Hematology. 2016;1:348–55.
628.
Brown AL, Hahn CN, Scott HS. Secondary leukemia in patients with germline transcription factor mutations (RUNX1, GATA2, CEBPA). Blood. 2020;136:24–35.PubMedPubMedCentralCrossRef
629.
630.
Visconte V, Nakashima MO, Rogers HJ. Mutations in splicing factor genes in myeloid malignancies: significance and impact on clinical features. Cancers (Basel). 2019;11:1844.CrossRef
631.
Falini B, Brunetti L, Martelli MP. How I diagnose and treat NPM1-mutated AML. Blood. 2021;137:589–99.PubMedCrossRef
632.
633.
Lavallée VP, Lemieux S, Boucher G, Gendron P, Boivin I, Girard S, et al. Identification of MYC mutations in acute myeloid leukemias with NUP98-NSD1 translocations. Leukemia. 2016;30:1621–4.PubMedCrossRef
634.
Bulaeva E, Pellacani D, Nakamichi N, Hammond CA, Beer P, Lorzadeh A, et al. MYC-induced human acute myeloid leukemia requires a continuing IL3/GM-CSF co-stimulus. Blood. 2020;136:2764–73.PubMedCrossRef
635.
Mudgapalli N, Nallasamy P, Chava H, Chava S, Pathania AS, Gunda V, et al. The role of exosomes and MYC in therapy resistance of acute myeloid leukemia: challenges and opportunities. Mol Aspects Med. 2019;70:21–32.PubMedPubMedCentralCrossRef
636.
Beverly LJ, Varmus HE. MYC-induced myeloid leukemogenesis is accelerated by all six members of the antiapoptotic BCL family. Oncogene. 2009;28:1274–9.PubMedPubMedCentralCrossRef
637.
Xiang Z, Luo H, Payton JE, Cain J, Ley TJ, Opferman JT, et al. Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia. J Clin Invest. 2010;120:2109–18.PubMedPubMedCentralCrossRef
638.
Müller-Tidow C, Steffen B, Cauvet T, Tickenbrock L, Ji P, Diederichs S, et al. Translocation products in acute myeloid leukemia activate the wnt signaling pathway in hematopoietic cells. Mol Cell Biol. 2004;24:2890–904.PubMedPubMedCentralCrossRef
639.
Puccetti E, Ruthardt M. Acute promyelocytic leukemia: PML/RARα and the leukemic stem cell. Leukemia. 2004;185:1169–75.CrossRef
640.
641.
Chong PSY, Zhou J, Chooi JY, Chan ZL, Toh SHM, Tan TZ, et al. Non-canonical activation of β-catenin by PRL-3 phosphatase in acute myeloid leukemia. Oncogene. 2019;38:1508–19.PubMedCrossRef
642.
Zhou J, Bi C, Chng WJ, Cheong LL, Liu SC, Mahara S, et al. PRL-3, a metastasis associated tyrosine phosphatase, is involved in FLT3-ITD signaling and implicated in anti-aml therapy. PLoS ONE. 2011;6:e19798.PubMedPubMedCentralCrossRef
643.
Ji H, Chen L, Xing Y, Li S, Dai J, Zhao P, et al. CD82 supports survival of childhood acute myeloid leukemia cells via activation of Wnt/β-catenin signaling pathway. Pediatr Res. 2019;85:1024–31.PubMedCrossRef
644.
Xu Y, Man N, Karl D, Martinez C, Liu F, Sun J, et al. TAF1 plays a critical role in AML1-ETO driven leukemogenesis. Nat Commun. 2019;10:1–15.CrossRef
645.
Mäkelä E, Löyttyniemi E, Salmenniemi U, Kauko O, Varila T, Kairisto V, et al. Arpp19 promotes Myc and Cip2a expression and associates with patient relapse in acute myeloid leukemia. Cancers (Basel). 2019;11:1774.CrossRef
646.
Schnittger S, Schoch C, Dugas M, Kern W, Staib P, Wuchter C, et al. Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease. Blood. 2002;100:59–66.PubMedCrossRef
647.
Kajiguchi T, Chung EJ, Lee S, Stine A, Kiyoi H, Naoe T, et al. FLT3 regulates β-catenin tyrosine phosphorylation, nuclear localization, and transcriptional activity in acute myeloid leukemia cells. Leukemia. 2007;21:2476–84.PubMedCrossRef
648.
Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, et al. Disruption of wnt/b-catenin exerts antileukemia activity and synergizes with flt3 inhibition in flt3-mutant acute myeloid leukemia. Clin Cancer Res. 2018;24:2417–29.PubMedPubMedCentralCrossRef
649.
Lee JK, Scarpa M, Kapoor S, Baer MR. Abstract 2056: Combined FLT3 and Pim kinase inhibitor treatment downregulates c-Myc early in apoptosis induction in acute myeloid leukemia with FLT3-ITD. Cancer Res. 2019;79:2056–2056.CrossRef
650.
Scarpa M, Singh P, Kapoor S, Lee JK, Niyongere S, Narla G, et al. PP2A activators enhance efficacy of FLT3 inhibitors in FLT3-ITD acute myeloid leukemia cells through AKT Inactivation-dependent Pim-1 and c-Myc proteasomal degradation. Blood. 2019;134:1276.CrossRef
651.
Ge Y, Schuster MB, Pundhir S, Rapin N, Bagger FO, Sidiropoulos N, et al. The splicing factor RBM25 controls MYC activity in acute myeloid leukemia. Nat Commun. 2019;10:1–14.CrossRef
652.
653.
Mitelman F, Johansson BMF. Mitelman database of chromosome aberrations and gene fusions in cancer. Ann Arbor: University Library; 2020.
654.
Huh YO, Tang G, Talwalkar SS, Khoury JD, Ohanian M, Bueso-Ramos CE, et al. Double minute chromosomes in acute myeloid leukemia, myelodysplastic syndromes, and chronic myelomonocytic leukemia are associated with micronuclei, MYC or MLL amplification, and complex karyotype. Cancer Genet. 2016;209:313–20.PubMedCrossRef
655.
Amin AJ, Shaw M, Tadros J, Benn H, Maroules M. Double minute chromosome in acute myeloid leukemia. Blood Am Soc Hematol. 2006;108:4428–4428.
656.
L’Abbate A, Tolomeo D, Cifola I, Severgnini M, Turchiano A, Augello B, et al. MYC-containing amplicons in acute myeloid leukemia: genomic structures, evolution, and transcriptional consequences. Leukemia. 2018;32:2152–66.PubMedCentralCrossRef
657.
Boddu P, Chihara D, Masarova L, Pemmaraju N, Patel KP, Verstovsek S. The co-occurrence of driver mutations in chronic myeloproliferative neoplasms. Ann Hematol. 2018;97:2071–80.PubMedCrossRef
658.
Ghalesardi OK, Khosravi A, Azizi E, Ahmadi SE, Hajifathali A, Bonakchi H, et al. The prognostic importance of BCR-ABL transcripts in chronic myeloid leukemia: a systematic review and meta-analysis. Leuk Res. 2021;101:106512.PubMedCrossRef
659.
Pan C, Olsen JV, Daub H, Mann M. Global effects of kinase inhibitors on signaling networks revealed by quantitative phosphoproteomics. Mol Cell Proteomics. 2009;8:2796–808.PubMedPubMedCentralCrossRef
660.
Lucas CM, Harris RJ, Giannoudis A, Copland M, Slupsky JR, Clark RE. Cancerous inhibitor of PP2A (CIP2A) at diagnosis of chronic myeloid leukemia is a critical determinant of disease progression. Blood. 2011;117:6660–8.PubMedCrossRef
661.
Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, et al. c-MYC oncoprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myelogenous leukemia CD34 + hematopoietic progenitor cells. Mol Cancer Res. 2011;9:1054–66.PubMedCrossRef
662.
Giannoudis A, Davies A, Harris RJ, Lucas CM, Pirmohamed M, Clark RE. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia. 2014;28:1360–3.PubMedCrossRef
663.
Beretta GL, Cassinelli G, Pennati M, Zuco V, Gatti L. Overcoming ABC transporter-mediated multidrug resistance: the dual role of tyrosine kinase inhibitors as multitargeting agents. Eur J Med Chem. 2017;142:271–89.PubMedCrossRef
664.
Reavie L, Buckley SM, Loizou E, Takeishi S, Aranda-Orgilles B, Ndiaye-Lobry D, et al. Regulation of c-Myc ubiquitination controls chronic myelogenous leukemia initiation and progression. Cancer Cell. 2013;23:362–75.PubMedPubMedCentralCrossRef
665.
Yeh CH, Bellon M, Nicot C. FBXW7: A critical tumor suppressor of human cancers. Mol Cancer. 2018;17:1–19.CrossRef
666.
Graham SM, Jørgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, et al. Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002;99:319–25.PubMedCrossRef
667.
Abraham SA, Hopcroft LEM, Carrick E, Drotar ME, Dunn K, Williamson AJK, et al. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells. Nature. 2016;534:341–6.PubMedPubMedCentralCrossRef
668.
Levine RL, Pardanani A, Tefferi A, Gilliland DG. Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders. Nat Rev Cancer. 2007;7:673–83.PubMedCrossRef
669.
Pearson S, Williamson AJK, Blance R, Somervaille TCP, Taylor S, Azadbakht N, et al. Proteomic analysis of JAK2V617F-induced changes identifies potential new combinatorial therapeutic approaches. Leukemia. 2017;31:2717–25.PubMedPubMedCentralCrossRef
670.
Wernig G, Gonneville JR, Crowley BJ, Rodrigues MS, Reddy MM, Hudon HE, et al. The Jak2V617F oncogene associated with myeloproliferative diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-oncogenes. Blood. 2008;111:3751–9.PubMedPubMedCentralCrossRef
671.
Huang SMA, Wang A, Greco R, Li Z, Barberis C, Tabart M, et al. Combination of PIM and JAK2 inhibitors synergistically suppresses MPN cell proliferation and overcomes drug resistance. Oncotarget. 2014;5:3362.PubMedPubMedCentralCrossRef
672.
Berg T, Cohen SB, Desharnais J, Sonderegger C, Maslyar DJ, Goldberg J, et al. Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts. Proc Natl Acad Sci U S A. 2002;99:3830–5.PubMedPubMedCentralCrossRef
673.
Xu Y, Shi J, Yamamoto N, Moss JA, Vogt PK, Janda KD. A credit-card library approach for disrupting protein-protein interactions. Bioorganic Med Chem. 2006;14:2660–2673675.CrossRef
674.
Sayyadi M, Safaroghli-Azar A, Pourbagheri-Sigaroodi A, Abolghasemi H, Anoushirvani AA, Bashash D. c-Myc inhibition using 10058–F4 increased the sensitivity of acute promyelocytic leukemia cells to arsenic trioxide via blunting PI3K/NF-κB axis. Arch Med Res. 2020;51:636–44.PubMedCrossRef
675.
Lao-On U, Rojvirat P, Chansongkrow P, Phannasil P, Siritutsoontorn S, Charoensawan V, et al. c-Myc directly targets an over-expression of pyruvate carboxylase in highly invasive breast cancer. Biochim Biophys Acta Mol Basis Dis. 2020;1866:165656.PubMedCrossRef
676.
Wang XN, Su XX, Cheng SQ, Sun ZY, Huang ZS, Ou TM. MYC modulators in cancer: a patent review. Expert Opin Ther Pat. 2019;29:353–67.PubMedCrossRef
677.
678.
AlSultan D, Kavanagh E, O’Grady S, Eustace AJ, Castell A, Larsson LG, et al. The novel low molecular weight MYC antagonist MYCMI-6 inhibits proliferation and induces apoptosis in breast cancer cells. Invest New Drugs. 2021;39:587–94.PubMedCrossRef
679.
Rihawi K, Alfieri R, Fiorentino M, Fontana F, Capizzi E, Cavazzoni A, et al. MYC amplification as a potential mechanism of primary resistance to crizotinib in ALK-rearranged non-small cell lung cancer: a brief report. Transl Oncol. 2019;12:116–21.PubMedCrossRef
680.
Boike L, Cioffi AG, Majewski FC, Co J, Henning NJ, Jones MD, et al. Discovery of a functional covalent ligand targeting an intrinsically disordered cysteine within MYC. Cell Chem Biol. 2021;28:4–13.PubMedCrossRef
681.
Han H, Jain AD, Truica MI, Izquierdo-Ferrer J, Anker JF, Lysy B, et al. Small-molecule MYC inhibitors suppress tumor growth and enhance immunotherapy. Cancer Cell. 2019;36:483–97.PubMedPubMedCentralCrossRef
682.
Struntz NB, Chen A, Deutzmann A, Wilson RM, Stefan E, Evans HL, et al. Stabilization of the max homodimer with a small molecule attenuates Myc-driven transcription. Cell Chem Biol. 2019;26:711–23.PubMedCrossRef
683.
684.
Wang E, Sorolla A, Cunningham PT, Bogdawa HM, Beck S, Golden E, et al. Tumor penetrating peptides inhibiting MYC as a potent targeted therapeutic strategy for triple-negative breast cancers. Oncogene. 2019;38:140–50.PubMedCrossRef
685.
Montagne M, Beaudoin N, Fortin D, Lavoie CL, Klinck R, Lavigne P. The max b-HLH-LZ can transduce into cells and inhibit c-Myc transcriptional activities. PLoS ONE. 2012;7:e32172.PubMedPubMedCentralCrossRef
686.
Demma MJ, Hohn MJ, Sun A, Mapelli C, Hall B, Walji A, et al. Inhibition of Myc transcriptional activity by a mini-protein based upon Mxd1. FEBS Lett. 2020;594:1467–76.PubMedCrossRef
687.
Park BK, Gautam A, Maharjan S, Lee SI, Lee Y, Kwon HJ. Production of Anti-c-Myc monoclonal antibody inhibiting DNA binding of c-Myc and Max dimer by epitope peptide–CpG-DNA–liposome complex without carriers. Int J Pept Res Ther. 2019;25:75–82.CrossRef
688.
Ting TA, Chaumet A, Bard FA. Targeting c-Myc with a novel peptide nuclear delivery device. Sci Rep. 2020;10:1–13.CrossRef
689.
Wang H, Ramakrishnan A, Fletcher S, Prochownik EV. A quantitative, surface plasmon resonance-based approach to evaluating DNA binding by the c-Myc oncoprotein and its disruption by small molecule inhibitors. J Biol Methods. 2015;2:e18.PubMedCrossRef
690.
Lustig LC, Dingar D, Tu WB, Lourenco C, Kalkat M, Inamoto I, et al. Inhibiting MYC binding to the E-box DNA motif by ME47 decreases tumour xenograft growth. Oncogene. 2017;36:6830–7.PubMedCrossRef
691.
Madden SK, de Araujo AD, Gerhardt M, Fairlie DP, Mason JM. Taking the Myc out of cancer: toward therapeutic strategies to directly inhibit c-Myc. Mol Cancer. 2021;20:1–18.CrossRef
692.
Beaulieu ME, Jauset T, Massó-Vallés D, Martínez-Martín S, Rahl P, Maltais L, et al. Intrinsic cell-penetrating activity propels omomyc from proof of concept to viable anti-myc therapy. Sci Transl Med. 2019;11:eaar5012.PubMedPubMedCentralCrossRef
693.
694.
Yin X, Giap C, Lazo JS, Prochownik EV. Low molecular weight inhibitors of Myc–Max interaction and function. Oncogene. 2003;22:6151–9.CrossRefPubMed
695.
Fletcher S, Prochownik EV. Small-molecule inhibitors of the Myc oncoprotein. Biochim Biophys Acta Gene Regul Mech. 2015;1849:525–43.CrossRef
696.
Chauhan J, Wang H, Yap JL, Sabato PE, Hu A, Prochownik EV, et al. Discovery of methyl 4’-methyl-5-(7-nitrobenzo[c][1,2,5]oxadiazol-4-yl)-[1,1’-biphenyl]-3-carboxylate, an improved small-molecule inhibitor of c-Myc-max dimerization. ChemMedChem. 2014;9:2274–85.PubMedPubMedCentralCrossRef
697.
Lu H, Zhou Q, He J, Jiang Z, Peng C, Tong R, et al. Recent advances in the development of protein–protein interactions modulators: mechanisms and clinical trials. Signal Transduct Target Ther. 2020;5:1–23.
698.
Hart JR, Garner AL, Yu J, Ito Y, Sun M, Ueno L, et al. Inhibitor of MYC identified in a Kröhnke pyridine library. Proc Natl Acad Sci U S A. 2014;111:12556–61.PubMedPubMedCentralCrossRef
699.
Stellas D, Szabolcs M, Koul S, Li Z, Polyzos A, Anagnostopoulos C, et al. Therapeutic effects of an anti-Myc drug on mouse pancreatic cancer. J Natl Cancer Inst. 2014;106:dju320.PubMedCrossRef
700.
Ji W, Zhang W, Wang X, Shi Y, Yang F, Xie H, et al. c-myc regulates the sensitivity of breast cancer cells to palbociclib via c-myc/miR-29b-3p/CDK6 axis. Cell Death Dis. 2020;11:1–3.CrossRef
701.
702.
Chen L, Cheng B, Sun Q, Lai L. Ligand-based optimization and biological evaluation of N-(2,2,2-trichloro-1-(3-phenylthioureido)ethyl)acetamide derivatives as potent intrinsically disordered protein c-Myc inhibitors. Bioorg Med Chem Lett. 2021;31:127711.PubMedCrossRef
703.
Foley SA, Castell A, Kavanagh E, Synnott NC, Crown J, Larsson L-G, et al. MYC as a therapeutic target for the treatment of triple-negative breast cancer. J Clin Oncol. 2019;37:e12550.CrossRef
704.
705.
Bailly C, Vergoten G. Protein homodimer sequestration with small molecules: focus on PD-L1. Biochem Pharmacol. 2020;174:113821.PubMedCrossRef
706.
Lafita-Navarro MC, Blanco R, Mata-Garrido J, Liaño-Pons J, Tapia O, García-Gutiérrez L, et al. MXD1 localizes in the nucleolus, binds UBF and impairs rRNA synthesis. Oncotarget. 2016;7:69536.PubMedPubMedCentralCrossRef
707.
Jung KY, Wang H, Teriete P, Yap JL, Chen L, Lanning ME, et al. Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics. J Med Chem. 2015;58:3002–24.PubMedPubMedCentralCrossRef
708.
Kim H, Yoo M, Jung K-Y. A promising but challenging strategy for cancer treatment: disruption of Myc-Max heterodimerization. Int J Clin Pharmacol Pharmacother. 2016;1:2.CrossRef
709.
710.
Miller AJ, Chang A, Cunningham PN. Chronic microangiopathy due to DCR-MYC, a Myc-targeted short interfering RNA. Am J Kidney Dis. 2020;75:513–6.PubMedCrossRef
711.
712.
Liu Y, Li X, Zhu S, Zhang JG, Yang M, Qin Q, et al. Ectopic expression of MIR-494 inhibited the proliferation, invasion and chemoresistance of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther. 2015;22:729–38.PubMedCrossRef
713.
Devi GR, Beer TM, Corless CL, Arora V, Weller DL, Iversen PL. In vivo bioavailability and pharmacokinetics of a c-MYC antisense phosphorodiamidate morpholino oligomer, AVI-4126, in solid tumors. Clin Cancer Res. 2005;11:3930–8.PubMedCrossRef
714.
Lewin J, Soria JC, Stathis A, Delord JP, Peters S, Awada A, et al. Phase Ib trial with birabresib, a small-molecule inhibitor of bromodomain and extraterminal proteins, in patients with selected advanced solid tumors. J Clin Oncol. 2018;36:3007–14.PubMedCrossRef
715.
Csizmarik A, Hadaschik B, Kramer G, Nyirady P, Szarvas T. Mechanisms and markers of resistance to androgen signaling inhibitors in patients with metastatic castration-resistant prostate cancer. In: Urologic oncology: seminars and original investigations; 2021.
716.
Aggarwal RR, Schweizer MT, Nanus DM, Pantuck AJ, Heath EI, Campeau E, et al. A phase Ib/IIa study of the Pan-BET inhibitor ZEN-3694 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer. Clin Cancer Res. 2020;26:5338–47.PubMedPubMedCentralCrossRef
717.
Patel MR, Garcia-Manero G, Paquette R, Dinner S, Donnellan WB, Grunwald MR, et al. Phase 1 dose escalation and expansion study to determine safety, tolerability, pharmacokinetics, and pharmacodynamics of the BET inhibitor FT-1101 as a single agent in patients with relapsed or refractory hematologic malignancies. Blood. 2019;134(Supplement_1):3907. https://​doi.​org/​10.​1182/​blood-2019-124741.
718.
719.
Hilton J, Cristea MC, Voskoboynik M, Postel-Vinay S, Edenfield W, Gavai A, et al. Initial results from a phase I/IIa trial evaluating BMS-986158, an inhibitor of the bromodomain and extra-terminal (BET) proteins, in patients (pts) with advanced cancer. Ann Oncol. 2018;29:viii134.CrossRef
720.
721.
Sun Y, Han J, Wang Z, Li X, Sun Y, Hu Z. Safety and efficacy of bromodomain and extra-terminal inhibitors for the treatment of hematological malignancies and solid tumors: a systematic study of clinical trials. Front Pharmacol. 2021;11:2440.CrossRef
722.
Shapiro GI, LoRusso P, Dowlati A, Do KT, Jacobson CA, Vaishampayan U, et al. A phase 1 study of RO6870810, a novel bromodomain and extra-terminal protein inhibitor, in patients with NUT carcinoma, other solid tumours, or diffuse large B-cell lymphoma. Br J Cancer. 2021;124:744–53.PubMedCrossRef
723.
724.
Piha-Paul SA, Hann CL, French CA, Cousin S, Braña I, Cassier PA, et al. Phase 1 study of molibresib (GSK525762), a bromodomain and extra-terminal domain protein inhibitor, in NUT carcinoma and other solid tumors. JNCI Cancer Spectr. 2020;4:pkz093.PubMedCrossRef
725.
Mascarenhas J, Harrison C, Luptakova K, Christo J, Wang J, Mertz JA, et al. MANIFEST-2, a global, phase 3, Randomized, Double-Blind, Active-Control Study of CPI-0610 and Ruxolitinib Vs. Placebo and Ruxolitinib in JAK-Inhibitor-Naive Myelofibrosis Patients. Blood 2020;136(Supplement 1):43. https://​doi.​org/​10.​1182/​blood-2020-140901.
726.
Blum KA, Abramson J, Maris M, Flinn I, Goy A, Mertz J, et al. A phase I study of CPI-0610, a bromodomain and extra terminal protein (BET) inhibitor in patients with relapsed or refractory lymphoma. Ann Oncol. 2018;29:ii7.CrossRef
727.
Rhyasen GW, Hattersley MM, Yao Y, Dulak A, Wang W, Petteruti P, et al. AZD5153: a novel bivalent BET bromodomain inhibitor highly active against hematologic malignancies. Mol Cancer Ther. 2016;15:2563–74.PubMedCrossRef
728.
Bradbury RH, Callis R, Carr GR, Chen H, Clark E, Feron L, et al. Optimization of a series of bivalent triazolopyridazine based bromodomain and extraterminal inhibitors: the discovery of (3R)-4-[2-[4-[1-(3-methoxy-[1,2,4]triazolo[4,3-b]pyridazin-6-yl)-4-piperidyl]phenoxy]ethyl]-1,3-dimethyl-piperazin-2-one (AZD5153). J Med Chem. 2016;59:7801–17.PubMedCrossRef
729.
Takimoto-Shimomura T, Tsukamoto T, Maegawa S, Fujibayashi Y, Matsumura-Kimoto Y, Mizuno Y, et al. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2. Invest New Drugs. 2019;37:210–22.PubMedCrossRef
730.
Gerlach D, Tontsch-Grunt U, Baum A, Popow J, Scharn D, Hofmann MH, et al. The novel BETi BI 894999 represses super-enhancer associated transcription and synergizes with CDK9 inhibition in AML by induction of apoptosis. Oncogene. 2018;37:2687–701.PubMedPubMedCentralCrossRef
731.
Tron AE, Belmonte MA, Adam A, Aquila BM, Boise LH, Chiarparin E, et al. Discovery of Mcl-1-specific inhibitor AZD5991 and preclinical activity in multiple myeloma and acute myeloid leukemia. Nat Commun. 2018;9:1–14.CrossRef
732.
Maragno AL, Mistry P, Kotschy A, Szlavik Z, Murray J, Davidson J, et al. Abstract 4482: S64315 (MIK665) is a potent and selective Mcl1 inhibitor with strong antitumor activity across a diverse range of hematologic tumor models. Cancers. 2019;12:574.
733.
734.
735.
Lee J, Zhang LL, Wu W, Guo H, Li Y, Sukhanova M, et al. Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma. Blood Adv. 2018;2:2039–51.PubMedPubMedCentralCrossRef
736.
Moyo TK, Wilson CS, Moore DJ, Eischen CM. Myc enhances B-cell receptor signaling in precancerous B cells and confers resistance to Btk inhibition. Oncogene. 2017;36:4653–61.PubMedPubMedCentralCrossRef
737.
Reiff SD, Mantel R, Smith LL, Greene JT, Muhowski EM, Fabian CA, et al. The btk inhibitor arq 531 targets ibrutinib-resistant cll and richter transformation. Cancer Discov. 2018;8:1300–15.PubMedPubMedCentralCrossRef
738.
Rifaï K, Judes G, Idrissou M, Daures M, Bignon YJ, Penault-Llorca F, et al. SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer. Oncotarget. 2018;9:30661.PubMedPubMedCentralCrossRef
739.
Ecker J, Thatikonda V, Sigismondo G, Selt F, Valinciute G, Oehme I, et al. Reduced chromatin binding of MYC is a key effect of HDAC inhibition in MYC amplified medulloblastoma. Neuro Oncol. 2021;22:226–39.CrossRef
740.
Knipstein J, Gore L. Entinostat for treatment of solid tumors and hematologic malignancies. Expert Opin Investig Drugs. 2011;20:1455–67.PubMedCrossRef
741.
742.
Deng C, Lipstein MR, Scotto L, Jirau Serrano XO, Mangone MA, Li S, et al. Silencing c-Myc translation as a therapeutic strategy through targeting PI3Kδ and CK1ε in hematological malignancies. Blood. 2017;129:88–99.PubMedPubMedCentralCrossRef
743.
Kahl BS, Spurgeon SE, Furman RR, Flinn IW, Coutre SE, Brown JR, et al. Results of a phase I study of idelalisib, a PI3Kδ inhibitor, in patients with relapsed or refractory mantle cell lymphoma (MCL). Blood. 2014;123:3398–405.PubMedPubMedCentralCrossRef
744.
Oki Y, Kelly KR, Flinn I, Patel MR, Gharavi R, Ma A, et al. CUDC-907 in relapsed/refractory diffuse large B-cell lymphoma, including patients with MYC-alterations: results from an expanded phase I trial. Haematologica. 2017;102:1923.PubMedPubMedCentralCrossRef
745.
746.
Dyer MJS, Vogler M, Samuel J, Jayne S, Wagner S, Pritchard C, et al. Precision medicines for B-cell leukaemias and lymphomas; progress and potential pitfalls. Br J Haematol. 2013;6:725–33.CrossRef
747.
Qian C, Lai CJ, Bao R, Wang DG, Wang J, Xu GX, et al. Cancer network disruption by a single molecule inhibitor targeting both histone deacetylase activity and phosphatidylinositol 3-kinase signaling. Clin Cancer Res. 2012;18:4104–13.PubMedCrossRef
748.
Younes A, Berdeja JG, Patel MR, Flinn I, Gerecitano JF, Neelapu SS, et al. Safety, tolerability, and preliminary activity of CUDC-907, a first-in-class, oral, dual inhibitor of HDAC and PI3K, in patients with relapsed or refractory lymphoma or multiple myeloma: An open-label, dose-escalation, phase 1 trial. Lancet Oncols. 2016;17:622–31.CrossRef
749.
Chen Y, Peubez C, Smith V, Xiong S, Kocsis-Fodor G, Kennedy B, et al. CUDC-907 blocks multiple pro-survival signals and abrogates microenvironment protection in CLL. J Cell Mol Med. 2019;23:340–8.PubMedCrossRef
750.
Iijima S, Teraoka H, Date T, Tsukada K. DNA-activated protein kinase in Raji Burkitt’s lymphoma cells. Eur J Biochem. 1992;206:595–603.PubMedCrossRef
751.
Shortt J, Martin BP, Newbold A, Hannan KM, Devlin JR, Baker AJ, et al. Combined inhibition of PI3K-related DNA damage response kinases and mTORC1 induces apoptosis in MYC-driven B-cell lymphomas. Blood. 2013;121:2964–74.PubMedPubMedCentralCrossRef
752.
753.
Kanazawa S, Soucek L, Evan G, Okamoto T, Peterlin BM. c-Myc recruits P-TEFb for transcription, cellular proliferation and apoptosis. Oncogene. 2003;22:5707–11.PubMedCrossRef
754.
Marshall NF, Peng J, Xie Z, Price DH. Control of RNA polymerase II elongation potential by a novel carboxyl- terminal domain kinase. J Biol Chem. 1996;271:27176–83.PubMedCrossRef
755.
Gargano B, Amente S, Majello B, Lania L. P-TEFb is a crucial co-factor for Myc transactivation. Cell Cycle. 2007;6:2031–7.PubMedCrossRef
756.
Parry D, Guzi T, Shanahan F, Davis N, Prabhavalkar D, Wiswell D, et al. Dinaciclib (SCH 727965), a novel and potent cyclin-dependent kinase inhibitor. Mol Cancer Ther. 2010;9:2344–53.PubMedCrossRef
757.
Gregory GP, Hogg SJ, Kats LM, Vidacs E, Baker AJ, Gilan O, et al. CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo. Leukemia. 2015;29:1437–41.PubMedPubMedCentralCrossRef
758.
Goh KC, Novotny-Diermayr V, Hart S, Ong LC, Loh YK, Cheong A, et al. TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties. Leukemia. 2012;26:236–43.PubMedCrossRef
759.
Chen R, Tsai J, Thompson PA, Chen Y, Xiong P, Liu C, et al. The multi-kinase inhibitor TG02 induces apoptosis and blocks B-cell receptor signaling in chronic lymphocytic leukemia through dual mechanisms of action. Blood Cancer J. 2021;11:1–15.CrossRef
760.
Richters A, Doyle SK, Freeman DB, Lee C, Leifer BS, Jagannathan S, et al. Modulating androgen receptor-driven transcription in prostate cancer with selective CDK9 inhibitors. Cell Chem Biol. 2021;28:134–47.PubMedCrossRef
761.
Yang D, Hurley L. Structure of the biologically relevant g-quadruplex in the c-MYC promoter. Nucleosides Nucleotides Nucleic Acids. 2006;25:951–68.PubMedCrossRef
762.
763.
Paul R, Das T, Debnath M, Chauhan A, Dash J. G-quadruplex-binding small molecule induces synthetic lethality in breast cancer cells by inhibiting c-MYC and BCL2 expression. ChemBioChem. 2020;21:963–70.PubMedCrossRef
764.
Drygin D, Siddiqui-Jain A, O’Brien S, Schwaebe M, Lin A, Bliesath J, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 2009;69:7653–61.PubMedCrossRef
765.
Local A, Zhang H, Benbatoul KD, Folger P, Sheng X, Tsai CY, et al. APTO-253 stabilizes G-quadruplex DNA, inhibits MYC expression, and induces DNA damage in acute myeloid leukemia cells. Mol Cancer Ther. 2018;17:1177–86.PubMedCrossRef
766.
Shachaf CM, Felsher DW. Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy. Cancer Res. 2005;65:4471–4.PubMedCrossRef
767.
768.
Dorgalaleh A, Bahraini M, Ahmadi SE. Personalized anesthesia in hematology. In: Dabbagh A, editor. Personalized medicine in anesthesia, pain and perioperative medicine. Cham: Springer; 2021.
Metadata
Title
MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies
Authors
Seyed Esmaeil Ahmadi
Samira Rahimi
Bahman Zarandi
Rouzbeh Chegeni
Majid Safa
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2021
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/s13045-021-01111-4

Other articles of this Issue 1/2021

Journal of Hematology & Oncology 1/2021 Go to the issue

Editorial

Stop hate crimes and racism

Letter to the Editor

HLA alleles associated with asparaginase hypersensitivity in Chinese children

Review

Antibody-drug conjugates for the treatment of lymphoma: clinical advances and latest progress

Review

Contradictory roles of lipid metabolism in immune response within the tumor microenvironment

Review

Nanomaterials for cancer therapy: current progress and perspectives

Review

Oncolytic viruses encoding bispecific T cell engagers: a blueprint for emerging immunovirotherapies
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits